Wilson's disease is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene, leading to toxic copper accumulation in the liver, brain, and other organs.

Exam domain	One-glance essentials
Definition / diagnosis	*Autosomal-recessive ATP7B disorder on chromosome 13* causing defective biliary copper excretion and copper incorporation into ceruloplasmin ^[1]^[2] Copper accumulates in the liver, basal ganglia, cornea, kidneys and red cells ^[1]
Epidemiology / risks	Usually presents at 5–35 years; children more often have hepatic disease and older patients neuropsychiatric disease ^[1] Siblings of an affected patient have a 25% risk; *screen first-degree relatives* ^[2]
Core mechanism	ATP7B failure → ↓ copper incorporation into apoceruloplasmin + ↓ biliary excretion → low ceruloplasmin and hepatic copper overload ^[1] Hepatocyte injury releases free copper → urinary copper rises and extrahepatic deposition causes neurological, corneal, renal and haemolytic disease ^[1]
Clinical picture	*Young patient with unexplained hepatitis/cirrhosis or acute liver failure; neurological disease causes dysarthria, dystonia, parkinsonism and wing-beating tremor* ^[2]^[3] Kayser–Fleischer rings are nearly universal in neurological disease but may be absent in purely hepatic disease ^[1] Coombs-negative haemolytic anaemia is a key clue, especially with acute liver failure ^[3]
Investigations	*No single test is diagnostic: combine ceruloplasmin, 24-hour urinary copper, slit-lamp examination, hepatic copper and genetics using the Leipzig score; ≥4 establishes diagnosis ^[2] Typical thresholds: ceruloplasmin < 20 mg/dL, urine copper > 100 μg/day and hepatic copper ≥250 μg/g dry weight ^[1] Fulminant clues: low ALP, Coombs-negative haemolysis and AST:ALT > 2* ^[3]
Management	Symptomatic disease: copper chelation with penicillamine (+ pyridoxine) or trientine; treatment is lifelong ^[1] Trientine is preferred for neurological disease because penicillamine may initially worsen neurological symptoms ^[3] Zinc blocks intestinal copper absorption and is used for presymptomatic/maintenance treatment; *liver transplantation is an effective cure* for fulminant failure or refractory decompensation ^[2]
Complications	Acute liver failure, cirrhosis and portal-hypertension complications are the major threats ^[2]^[4] Irreversible neurological disability, Fanconi syndrome, nephrolithiasis and skeletal disease reflect extrahepatic copper toxicity ^[1] Penicillamine can cause neurological worsening, nephrotoxicity, myelosuppression and autoimmune disease ^[3]
Prevention / follow-up	*Screen first-degree relatives* with copper studies and slit-lamp examination; use targeted ATP7B testing when the proband's variants are known ^[2] Lifelong adherence, a low-copper diet and avoidance of alcohol/hepatotoxins prevent recurrence and progression ^[1]
Exam traps	Normal ceruloplasmin or absent KF rings does not exclude Wilson's disease ^[1] Total serum copper may be low despite toxic free copper being high ^[1] A negative ATP7B test does not exclude disease because of marked allelic heterogeneity ^[2] *Liver transplantation is not indicated solely for neurological disease* ^[2]

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease) ^[2] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease slides) ^[3] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf (Wilson's disease) ^[4] Lecture slides: GC 026. Abdominal distension_ascites and cirrhosis.pdf (The Cirrhotic Patient: One-Slide Overview)

Wilson's Disease

Wilson's disease (also known as hepatolenticular degeneration) is a genetic disorder of copper metabolism inherited in an autosomal recessive (AR) manner, caused by mutations in the ATP7B gene on chromosome 13 ^[1]^[2]^[3]. The name breaks down neatly: "hepato-" = liver, "lenticular" = lentiform nucleus (part of the basal ganglia), "degeneration" = progressive damage — telling you the two principal targets of the disease.

The core defect is impairment of cellular copper (Cu²⁺) transport, resulting in a defective protein that fails in copper incorporation into ceruloplasmin and biliary copper excretion, leading to accumulation of copper in several organs, most notably the liver, brain, and cornea ^[2]^[4].

High Yield – GC Lecture Point

Wilson's disease is a metabolic cause of liver failure and should always be considered in any young patient presenting with unexplained liver disease, neuropsychiatric symptoms, or Coombs-negative haemolytic anaemia ^[5]^[6].

Parameter	Detail
Prevalence	1 in 30,000 live births in most populations ^[2]^[3] (Adrian Lui Paeds notes cite 1/200k — this likely refers to clinical prevalence vs genetic carrier prevalence)
Sex ratio	M:F ≈ 1:1 ^[2]^[3]
Female predominance in ALF	Females are more likely to develop acute liver failure (M:F = 1:4 for ALF specifically) ^[4]
Age at diagnosis	Mean age 12–23 years; majority diagnosed between 5–35 years ^[4]
Average onset	~13 years ^[1]
Carrier frequency	~1 in 90 (AR inheritance)
Genetic vs clinical prevalence	Incomplete penetrance — genetic prevalence >> clinical prevalence ^[1]^[2]

Key epidemiological points to understand:

Children are more likely to present with hepatic manifestations ^[4]
Older patients (adolescents/young adults) are more likely to present with neurological manifestations ^[4]
This makes sense because copper accumulates in the liver first (from birth), and only once hepatocytes are damaged and release copper into the bloodstream does extrahepatic deposition (brain, cornea, kidneys) occur

Hong Kong Context

While Wilson's disease is rare globally, Hong Kong has a significant proportion of patients with chronic liver disease from HBV — Wilson's disease must be actively excluded in young patients with unexplained liver disease to avoid missing this treatable condition
The ATP7B mutation spectrum in Chinese/East Asian populations differs from European populations (most common mutation in Europeans is H1069Q; in East Asians it is R778L) ^[2]

Wilson's disease is a monogenic disorder, so "risk factors" in the traditional sense do not apply. However:

Family history — AR inheritance; siblings of an affected individual have a 25% chance of being affected
Consanguinity — increases homozygosity risk
Ethnicity — certain populations have higher carrier frequencies
Children diagnosed through family screening because of an affected sibling are often asymptomatic ^[4]

Anatomy and Normal Copper Physiology

To understand Wilson's disease, you must understand how copper is normally handled:

Dietary intake: ~2–5 mg/day from food (shellfish, nuts, chocolate, liver, mushrooms)
Absorption: Duodenum and proximal jejunum via copper transporter 1 (CTR1)
Portal circulation: Copper travels to the liver bound to albumin and histidine
Hepatocyte uptake: Copper enters hepatocytes via CTR1
Intracellular handling:
- Copper is bound by metallochaperones (e.g., ATOX1) which deliver it to specific compartments
- ATOX1 delivers copper to ATP7B in the trans-Golgi network
ATP7B functions (the critical protein):
- Incorporates copper into apoceruloplasmin → forming ceruloplasmin (holoceruloplasmin), which is then secreted into blood ^[1]^[2]^[3]
- Removes excessive copper by biliary secretion — this is the ONLY significant route for copper excretion from the body ^[4]
Ceruloplasmin: A copper-containing α2-globulin with ferroxidase activity (oxidises Fe²⁺ to Fe³⁺); carries ~90% of circulating copper
Biliary excretion: ~0.5–1.5 mg/day — matches dietary absorption to maintain copper balance

Organ	Anatomical target	Why it matters
Liver	Hepatocytes	First site of copper accumulation (ATP7B is mainly expressed in liver) ^[2]
Brain	Basal ganglia (lentiform nucleus = putamen + globus pallidus), cerebellum, brainstem	Extrapyramidal motor symptoms
Eyes	Descemet's membrane (cornea), lens	Kayser-Fleischer rings, sunflower cataracts
Kidneys	Proximal tubules	Fanconi syndrome
Blood	Red blood cells	Haemolytic anaemia
Joints	Articular cartilage	Arthropathy, chondrocalcinosis
Heart	Myocardium	Cardiomyopathy (rare)

Aetiology and Pathophysiology

ATP7B gene on chromosome 13 encodes a copper-transporting P-type ATPase (the "Wilson disease protein") ^[1]^[2]^[3]^[4]
The "P-type ATPase" means it uses ATP hydrolysis to pump copper across membranes (the "P" stands for phosphorylation of the enzyme during the transport cycle)
> 200 different mutations identified ^[1]^[2]
Most cases are compound heterozygotes ^[1]^[2]^[4] — meaning patients carry two different mutations in ATP7B, one on each chromosome 13
- This is why genetic testing does not have to be positive to reach a diagnosis — the hereditary pathway of Wilson's is very heterogeneous; not just one ATP7B mutation ^[7]
- A negative genetic test does NOT exclude Wilson's disease if clinical and biochemical features are compatible

Compound Heterozygosity – Exam Concept

Compound heterozygotes = having 2 heterozygous recessive alleles at a particular locus that cause genetic disease in a heterozygous state. Identification of two mutations on opposite chromosomes, both heterozygous recessive alleles affecting the same gene ATP7B ^[4]. This explains why genetic testing can be challenging — you need to find BOTH mutations, and many are private/rare.

Let me walk through this:

Mutation of ATP7B results in impaired incorporation of copper into apoceruloplasmin ^[2]
- Apoceruloplasmin has shorter t½ than ceruloplasmin → ↓ plasma ceruloplasmin levels ^[1]^[2]
- This is why low ceruloplasmin is a hallmark finding — the apo- form (without copper) is degraded much faster
Defective Cu excretion into bile → accumulates inside liver causing damage (↑ hepatic Cu) ^[3]
- Since biliary excretion is the ONLY significant exit route for copper, this is catastrophic
- Copper accumulation within hepatocytes occurs gradually since birth ^[1]
Damaged hepatocytes release stored Cu in free form → ↑ serum free Cu, ↑ 24h urine Cu ^[3]
- The distinction between free (non-ceruloplasmin-bound) copper and total copper is critical
- Total serum copper is actually LOW (because ceruloplasmin-bound copper is reduced)
- But FREE copper is HIGH (because damaged hepatocytes dump unbound copper)
↑ Free serum copper concentration → extrahepatic copper deposition, especially the brain, kidney, cornea ^[1]

Why Liver First, Brain Later?

The liver is affected first because ATP7B is mainly expressed there — copper accumulates in hepatocytes from birth. Neurological manifestations come later because they depend on copper being RELEASED from damaged hepatocytes into the circulation, which then deposits in the brain. This is why children present with liver disease and older patients present with neurological features ^[4].

Pathophysiology of Specific Organ Damage

Direct copper toxicity to hepatocytes:
- Oxidative stress: Free copper catalyses Fenton-like reactions → reactive oxygen species (ROS) → lipid peroxidation → membrane damage
- Mitochondrial dysfunction: Copper accumulates in mitochondria → impaired oxidative phosphorylation
- Apoptosis and necrosis: Progressive hepatocyte death
Spectrum: steatosis → chronic hepatitis → fibrosis → cirrhosis → acute liver failure

Copper deposits predominantly in the basal ganglia (especially putamen and caudate), cerebellum, and brainstem
Mechanism: copper-induced oxidative damage to neurons, demyelination, astrocyte swelling (Alzheimer type II astrocytosis)
Can mimic Parkinson's disease — extrapyramidal deposition of copper ^[7]

Copper deposits in Descemet's membrane of the cornea ^[3]
Descemet's membrane is the basement membrane of corneal endothelium — it preferentially binds copper due to its sulfur-rich composition
Appears as a golden-brown ring at the limbus (junction of cornea and sclera), best seen on slit-lamp examination

Copper deposits in proximal tubules → tubular dysfunction → Fanconi syndrome
Fanconi syndrome = generalised proximal tubule transport defect → aminoaciduria, glycosuria (normoglycaemic), phosphaturia, bicarbonaturia (type 2 RTA), uricosuria

Coombs-negative haemolytic anaemia ^[3]^[7]
Mechanism: copper released from damaged hepatocytes deposits in RBC membranes → oxidative damage → intravascular haemolysis
Coombs negative because this is NOT immune-mediated — it's direct toxicity
Fulminant hepatic failure due to Wilson's has a very specific feature: young patients with no reason for fulminant liver failure, exclusion of all other common causes → only finding is low haemoglobin → Coombs-negative haemolytic anaemia ^[7]

Classification

Wilson's disease can be classified by mode of presentation:

Type	Typical Age	Features
Hepatic	Children, early adolescence	Acute hepatitis, chronic hepatitis, cirrhosis, acute liver failure
Neurological	Late adolescence, young adults	Extrapyramidal symptoms, cerebellar signs, psychiatric
Mixed	Variable	Both hepatic and neurological
Other	Variable	Renal, haematological, musculoskeletal, cardiac

Acute hepatitis — clinically indistinguishable from acute viral hepatitis
Chronic hepatitis — often asymptomatic, chronically elevated ALT/AST
Cirrhosis — present in ~35–45% of patients at time of diagnosis ^[1]
Fulminant hepatic failure (8–12%) — may be associated with massive release of free copper into bloodstream ^[1]

The Leipzig score is the standardised diagnostic scoring system for Wilson's disease, incorporating clinical, biochemical, and genetic parameters ^[3]. (Detailed in the diagnostic criteria section to follow.)

Clinical Features

Course: universally fatal if untreated; majority die from liver failure ^[1]
Liver diseases may progress silently in patients until adolescence when complications of cirrhosis or acute liver failure may develop ^[4]
Onset usually between 5–35 years (average 13 years) ^[1]

Symptoms

The liver is the first organ affected ^[1]^[4].

Symptom	Pathophysiological Basis
Jaundice	Hepatocyte damage → impaired bilirubin conjugation and excretion; in acute liver failure, massive hepatocyte necrosis releases unconjugated and conjugated bilirubin
Abdominal pain (RUQ)	Hepatic inflammation → Glisson's capsule distension (the liver parenchyma itself has no pain fibres; pain comes from the capsule)
Fatigue, malaise	Impaired hepatic synthetic and metabolic function → accumulation of toxins, reduced energy substrate processing
Anorexia, nausea	Hepatic inflammation, portal hypertension → gastric/intestinal congestion
Easy bruising/bleeding	Impaired hepatic synthesis of coagulation factors (II, VII, IX, X) and reduced thrombopoietin → thrombocytopenia (also from hypersplenism)
Abdominal distension	Ascites from portal hypertension (↑ hydrostatic pressure in splanchnic bed + ↓ albumin → ↓ oncotic pressure)
Leg swelling	Hypoalbuminaemia → reduced plasma oncotic pressure; also from portal hypertension-related fluid retention

Hepatic presentations include: persistently elevated serum aminotransferases, chronic hepatitis, cirrhosis, fulminant hepatic failure ^[8]

Neurological presentations are due to copper deposition in the basal ganglia, cerebellum, and brainstem ^[1]^[8].

Symptom	Pathophysiological Basis
Dysarthria (85–97%)	Cerebellar and/or extrapyramidal dysfunction → poor coordination of speech muscles; can be ataxic, athetoid, hypophonic, or spastic ^[1]
Tremor	Basal ganglia copper deposition → disruption of normal motor circuits; classically "wing-beating tremor" = coarse, irregular, proximal arm tremor (arms outstretched, like a bird flapping wings) — this is a postural/kinetic tremor from cerebellar involvement ^[3]^[8]
Dystonia (11–69%)	Basal ganglia damage → sustained involuntary muscle contractions; can include blepharospasm (involuntary eyelid closure), torticollis ^[1]
Gait abnormalities and ataxia (30–75%)	Cerebellar involvement → wide-based, uncoordinated gait ^[1]
Choreiform movements	Basal ganglia (caudate/putamen) damage → loss of normal movement suppression → involuntary, irregular, flowing movements ^[8]
Parkinsonism	Copper deposition in basal ganglia can mimic Parkinson's disease ^[7]^[8] → bradykinesia, rigidity, rest tremor
Pseudobulbar palsy	Bilateral upper motor neuron lesions to brainstem nuclei → dysphagia, emotional lability, brisk jaw jerk ^[8]
Seizures	Cortical copper deposition → neuronal hyperexcitability ^[8]
Drooling	Dysphagia + poor oropharyngeal coordination from extrapyramidal/bulbar dysfunction
Difficulty writing	Fine motor dysfunction from extrapyramidal and/or cerebellar involvement

Wilson's Disease in the DDx of Movement Disorders

Wilson's disease must always be in the differential for secondary (symptomatic) parkinsonism in young patients ^[9]. It is also a cause of dystonia, chorea, and cerebellar ataxia in young adults. The key teaching point: always check ceruloplasmin and copper studies in any young patient with unexplained movement disorder.

Psychiatric manifestations can precede or accompany neurological features and are due to copper deposition in the cerebral cortex and limbic system ^[8].

Symptom	Pathophysiological Basis
Depression	Frontal lobe and limbic copper deposition → disruption of serotonergic/dopaminergic pathways ^[8]
Personality changes	Frontal lobe dysfunction → disinhibition, apathy, irritability ^[8]
Neurosis	Generalised cortical dysfunction ^[8]
Psychosis	Dopaminergic pathway disruption in mesolimbic system ^[8]
Cognitive decline	Diffuse cortical copper deposition
Behavioural problems (in children)	Early cortical involvement; often misattributed to adolescent issues

A critical pitfall: patients may first present to psychiatry and be misdiagnosed with a primary psychiatric disorder for years before the true diagnosis is made.

Symptom	Pathophysiological Basis
Haematuria	Renal copper deposition → tubular damage ^[3]
Polyuria, polydipsia	Fanconi syndrome → osmotic diuresis from glycosuria and impaired concentrating ability
Bone pain/fractures	Osteoporosis from Fanconi syndrome (phosphaturia → hypophosphataemia → impaired mineralisation); also from chronic liver disease
Joint pain/swelling	Copper deposition in cartilage → premature osteoarthritis, CPPD crystal deposition (Wilson's disease is an associated metabolic cause of CPPD disease) ^[10]
Menstrual irregularity/amenorrhoea	Chronic liver disease → impaired oestrogen metabolism; copper toxicity to reproductive organs

Signs

Sign	Pathophysiological Basis
Jaundice	As above — hepatocellular damage
Hepatomegaly (early)	Copper-laden, inflamed liver; may be replaced by a shrunken liver in advanced cirrhosis
Splenomegaly	Portal hypertension → congestion of splenic sinusoids
Ascites	Portal hypertension (↑ splanchnic hydrostatic pressure) + hypoalbuminaemia (↓ oncotic pressure) + RAAS activation (Na⁺/water retention)
Spider naevi	Hyperoestrogenism from impaired hepatic oestrogen metabolism → arteriolar vasodilation
Palmar erythema	Same mechanism as spider naevi
Caput medusae	Portal hypertension → porto-systemic anastomosis at umbilical vein
Flapping tremor (asterixis)	Hepatic encephalopathy → metabolic disturbance of reticular activating system
Gynaecomastia	Hyperoestrogenism in males
Dupuytren's contracture	Hepatic fibrosis → (mechanism incompletely understood, associated with chronic liver disease)

Ophthalmic: Kayser-Fleischer rings, sunflower cataracts ^[8]

Sign	Pathophysiological Basis
Kayser-Fleischer (KF) rings	Copper deposits in Descemet's membrane of the cornea → golden-brown/greenish ring at the corneal periphery (limbus) ^[3]. Best detected by slit-lamp examination. Present in 99% of patients with neuropsychiatric symptoms and 30–50% with hepatic symptoms ^[3]
Sunflower cataracts	Copper deposits in the lens → distinctive petal-like, sunflower appearance ^[3]. Less common than KF rings. Does not usually impair vision significantly

KF Rings – Must Know

KF rings are NOT pathognomonic for Wilson's disease (they can rarely occur in other cholestatic liver diseases such as PBC). However, in a young patient with liver disease or neurological symptoms, KF rings are virtually diagnostic. The absence of KF rings does NOT exclude Wilson's disease — they are absent in up to 50–70% of patients with purely hepatic presentations ^[3].

Sign	Pathophysiological Basis
Resting tremor	Basal ganglia copper deposition → dopaminergic circuit disruption (Parkinsonian)
Wing-beating tremor	Cerebellar copper deposition → coarse, proximal, postural tremor
Rigidity (cogwheel or lead-pipe)	Basal ganglia damage → loss of normal inhibition of muscle tone
Bradykinesia	Striatal dopaminergic pathway disruption
Dystonia	Copper deposition in putamen → abnormal sustained postures
Chorea	Caudate nucleus damage → involuntary irregular movements
Cerebellar signs	Ataxia, dysmetria, dysdiadochokinesia, intention tremor, nystagmus — from cerebellar copper deposition
Pseudobulbar palsy	Bilateral UMN lesions → brisk jaw jerk, spastic dysarthria, dysphagia, emotional lability ^[8]
Risus sardonicus ("sardonic grin")	Dystonia of facial muscles — characteristic facies in advanced Wilson's disease

Sign	Pathophysiological Basis
Fanconi's syndrome	Proximal tubule transport defect due to copper deposition ^[3]: aminoaciduria, glycosuria, phosphaturia (→ hypophosphataemia, rickets/osteomalacia), uricosuria (→ low uric acid), bicarbonate wasting (→ Type 2/proximal RTA → metabolic acidosis)
Renal tubular acidosis	Bicarbonate wasting from proximal tubule damage
Nephrolithiasis	Hypercalciuria, hyperuricosuria from tubular dysfunction

Sign	Pathophysiological Basis
Coombs-negative haemolytic anaemia	Cu deposit in RBC membranes → oxidative damage → intravascular haemolysis. Coombs-negative because it is NOT antibody-mediated ^[3]^[7]
Thrombocytopenia	Hypersplenism from portal hypertension
Leucopoenia	Hypersplenism

Fulminant Wilson's – Classic Exam Scenario

Fulminant hepatic failure due to Wilson's has a very specific feature: young patients with no reason for fulminant liver failure, exclusion of all other common causes → only finding is low haemoglobin → Coombs-negative haemolytic anaemia ^[7]. The combination of acute liver failure + Coombs-negative haemolytic anaemia + low ALP (paradoxically, because ALP is a zinc-dependent enzyme and zinc is competitively displaced by excess copper) is highly suggestive of Wilson's disease. AST/ALT ratio > 2 is also a clue ^[3].

Sign	Pathophysiological Basis
Premature osteoarthritis	Copper deposition in articular cartilage → chondrocyte damage
Chondrocalcinosis	CPPD crystal deposition (Wilson's is a recognised metabolic disease associated with CPPD) ^[10]
Osteoporosis	Vitamin D deficiency (from Fanconi syndrome phosphaturia), chronic liver disease

Sign	Detail
Blue lunulae	Copper deposition in nail beds → bluish discolouration of the half-moon at the nail base
Cardiomyopathy	Copper deposition in myocardium → dilated or hypertrophic cardiomyopathy (rare)
Pancreatitis	Copper deposition in pancreas (rare)

System	Key Features	Mechanism
Liver	Acute hepatitis, chronic hepatitis, cirrhosis, fulminant liver failure	Direct copper toxicity → hepatocyte damage
CNS	Dysarthria, tremor (wing-beating), dystonia, Parkinsonism, chorea, ataxia, pseudobulbar palsy, seizures	Copper deposition in basal ganglia, cerebellum, brainstem
Psychiatric	Depression, personality changes, psychosis, neurosis	Copper deposition in cortex/limbic system
Eyes	KF rings, sunflower cataracts	Copper in Descemet's membrane and lens
Kidneys	Fanconi syndrome, haematuria, RTA	Copper toxicity to proximal tubules
Blood	Coombs-negative haemolytic anaemia	Copper in RBC membranes → oxidative haemolysis
MSK	Osteoarthritis, chondrocalcinosis, osteoporosis	Copper in cartilage + Fanconi phosphaturia
Cardiac	Cardiomyopathy, arrhythmias	Copper deposition in myocardium

High Yield Summary

Wilson's disease = AR mutation in ATP7B gene on chromosome 13 → defective copper-transporting P-type ATPase
Two key functional losses: failure to incorporate copper into ceruloplasmin + failure to excrete copper into bile
Copper accumulates in liver first (from birth) → hepatocyte damage → copper spills into blood → deposits in brain, cornea, kidneys, RBCs
Children present with hepatic disease; older patients with neurological/psychiatric disease
KF rings (Descemet's membrane) present in 99% with neuropsychiatric and 30–50% with hepatic disease
Coombs-negative haemolytic anaemia is the hallmark haematological manifestation — non-immune, direct copper toxicity to RBCs
Fulminant liver failure + Coombs-negative haemolytic anaemia + low ALP in a young patient = think Wilson's
Most patients are compound heterozygotes; > 200 mutations identified
Universally fatal if untreated
Genetic test does not have to be positive to diagnose — clinical + biochemical diagnosis is sufficient given the genetic heterogeneity
Wilson's disease is a recognised metabolic cause of CPPD crystal deposition disease
Can mimic Parkinson's disease — always check copper studies in young-onset parkinsonism

Active Recall - Wilson's Disease (Part 1: Definition to Clinical Features)

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease) ^[2] Senior notes: Ryan Ho GI.pdf (Section 4.5.3 – Wilson's Disease) ^[3] Senior notes: Maksim Medicine Notes.pdf (Wilson's disease) ^[4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease) ^[5] Lecture slides: GC 025. A jaundiced and incoherent patient liver failure.pdf ^[6] Senior notes: Block A - A jaundiced and incoherent patient_ liver failure.pdf ^[7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf ^[8] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease slide) ^[9] Senior notes: Ryan Ho Neurology.pdf (Section on secondary parkinsonism) ^[10] Senior notes: Ryan Ho Rheumatology.pdf (CPPD crystal deposition disease)

Differential Diagnosis of Wilson's Disease

Wilson's disease is a diagnostic chameleon. Its protean manifestations span hepatology, neurology, psychiatry, haematology, nephrology and ophthalmology. Because it is rare (1 in 30,000) yet treatable and universally fatal if untreated ^[1], the clinician's task is twofold:

When you suspect Wilson's — confirm it efficiently.
When a patient presents with one of Wilson's phenotypes (unexplained liver disease, young-onset movement disorder, psychiatric change, Coombs-negative haemolysis) — keep Wilson's in the differential and not miss it.

The differential diagnosis is therefore best organised by presenting phenotype, because that is how you will encounter these patients in clinical practice and in exams.

This is the most common initial presentation of Wilson's disease, particularly in children and adolescents. The liver disease can range from asymptomatic transaminase elevation to acute hepatitis, chronic hepatitis, cirrhosis, or fulminant liver failure.

GC High Yield – Metabolic Causes of Chronic Liver Disease

Wilson's disease is classified as a metabolic cause of chronic liver disease alongside haemochromatosis and α1-antitrypsin deficiency ^[5]^[7]. In the GC lecture on non-viral chronic liver diseases, these three metabolic conditions are specifically highlighted as important differentials when common viral and alcoholic aetiologies have been excluded ^[8].

Differential	Key Distinguishing Features	Why it mimics Wilson's
Viral hepatitis (HBV, HCV, HAV, HEV)	Viral serology positive; HAV/HEV usually self-limiting; HBV/HCV can cause chronic disease. HBV extremely common in HK ^[11]^[12]	Acute hepatitis from Wilson's is clinically indistinguishable from acute viral hepatitis ^[1] — jaundice, abdominal pain, raised transaminases (though usually lower than viral)
Autoimmune hepatitis (AIH)	Autoantibodies (ANA, ASMA, anti-LKM1); elevated IgG; responds to immunosuppression; female predominance. Histological features of Wilson's are similar to autoimmune hepatitis and NASH including fatty infiltration, glycogen inclusions, portal fibrosis ^[4]	Can present at similar age; chronically elevated transaminases; autoantibodies are not specific and AIH sometimes becomes a diagnosis of exclusion ^[11]
NAFLD / NASH	Obesity, metabolic syndrome, insulin resistance; USS shows fatty liver; no KF rings, normal copper studies	Both can cause fatty liver on histology; Wilson's can cause hepatic steatosis in early stages
Drug-induced liver injury (DILI)	Temporal relationship with drug exposure; pattern (hepatocellular vs cholestatic vs mixed) depends on causative drug	Both present with elevated transaminases; important to take a thorough drug history
Alcoholic liver disease	Significant alcohol intake history; AST > ALT (usually AST:ALT ≈ 2:1) but AST rarely exceeds 500 ^[11]; GGT disproportionately elevated	Wilson's also has AST > ALT (ratio > 2) ^[3] — but occurs in a young patient without alcohol history, which is the key differentiator
α1-antitrypsin (A1AT) deficiency	Low serum α1-antitrypsin level; PiZZ phenotype; associated emphysema (panlobular, lower lobes); PAS-positive, diastase-resistant globules on liver biopsy	Both are AR metabolic causes of chronic liver disease in young patients
Hereditary haemochromatosis (HH)	Elevated ferritin and transferrin saturation; HFE gene mutation (C282Y, H63D); iron deposition on MRI; bronze diabetes, arthropathy	Both are inherited metabolic diseases causing chronic liver disease; both are risk factors for HCC ^[13]; haemochromatosis more common in Caucasians, much rarer in Hong Kong Chinese
Primary biliary cholangitis (PBC)	Middle-aged women; pruritus; M2 isoform of anti-mitochondrial antibody (AMA) is highly specific ^[7]; cholestatic LFT pattern (elevated ALP/GGT >> AST/ALT)	Rarely confused clinically, but both can cause KF rings (very rare in PBC — copper retention from chronic cholestasis can deposit in cornea)
Primary sclerosing cholangitis (PSC)	Male predominance; associated with IBD (especially UC); "beading" of bile ducts on MRCP; cholestatic pattern	Rarely mimics Wilson's but both can cause chronic liver disease

Critical Exam Point

HBV and HCV serology must be performed to rule out other differential diagnoses including chronic viral hepatitis ^[4]. In Hong Kong, HBV is the leading cause of chronic liver disease and HCC — it is essential to exclude this first. However, a positive HBsAg does NOT exclude coexisting Wilson's disease. Even if HBsAg is positive, it may not explain the current liver presentation ^[11] — always consider whether the clinical picture truly fits viral hepatitis alone.

How to Distinguish Wilson's from These Hepatic Mimics

The key discriminating investigations are:

Age: Wilson's presents in young patients (5–35 years); viral hepatitis can occur at any age
Low ceruloplasmin ( < 20 mg/dL): absent in other causes (though can be low in severe liver failure of any cause, malnutrition, nephrotic syndrome)
Elevated 24-hour urinary copper ( > 100 μg): relatively specific
KF rings on slit-lamp examination: present in ~30–50% with hepatic disease ^[3]
No single test is diagnostic ^[8] — diagnosis requires a combination of findings (Leipzig score)

Wilson's disease typically causes extrapyramidal symptoms (parkinsonism, dystonia, chorea) and/or cerebellar signs (ataxia, tremor, dysarthria). The differential here is essentially the differential for movement disorders in a young person.

Wilson's disease must be considered in the differential of secondary (symptomatic) parkinsonism ^[9]. Drug-induced parkinsonism from metoclopramide, antipsychotics, or antihistamines is particularly important to identify as it is reversible ^[14].

Differential	Key Distinguishing Features	Why it mimics Wilson's
Idiopathic Parkinson's disease (IPD)	Onset 40–70 years (peak 6th decade); unilateral onset; resting pill-rolling tremor; responds well to levodopa; Lewy body pathology ^[9]	Wilson's can mimic Parkinson's disease — extrapyramidal deposition of copper ^[7]. BUT Wilson's presents earlier (5–35y), often bilateral, and tremor is more often postural/kinetic (wing-beating) rather than pure resting
Drug-induced parkinsonism	Temporal relationship with offending drug (neuroleptics, metoclopramide, antiemetics, lithium); usually bilateral and symmetrical; resolves on drug withdrawal ^[9]	Both cause extrapyramidal signs in young people; drug history is the key
Huntington's disease	AD inheritance; CAG trinucleotide repeat on chromosome 4p16.3; chorea + psychiatric manifestations + progressive dementia ^[14]; caudate atrophy on MRI	Both can cause chorea and psychiatric symptoms in young patients; but Huntington's is AD (vs Wilson's AR), and typically presents later (30–50y) with chorea > parkinsonism
Progressive supranuclear palsy (PSP)	Older patients (> 60y); vertical gaze palsy (initially downgaze); axial rigidity > limb rigidity; frequent falls; poor levodopa response ^[9]	Both cause parkinsonism but PSP is an older-onset disease
Multiple system atrophy (MSA)	Older onset; prominent autonomic dysfunction (postural hypotension, urinary incontinence); cerebellar signs (MSA-C) or parkinsonism (MSA-P); poor levodopa response ^[9]	Both can cause cerebellar signs + parkinsonism, but MSA is older-onset
Neurodegeneration with brain iron accumulation (NBIA, Hallervorden-Spatz syndrome)	Childhood/adolescent onset; dystonia, parkinsonism; "eye-of-the-tiger" sign on MRI (iron deposition in globus pallidus) ^[9]	Both cause young-onset dystonia/parkinsonism; but NBIA has characteristic MRI and no copper abnormality
Toxic exposure (MPTP, manganese, CO poisoning)	Relevant exposure history; bilateral symmetrical parkinsonism ^[9]	Young onset parkinsonism — exposure history is key
Cerebral arteriosclerotic disease (vascular parkinsonism)	Stepwise deterioration; LL > UL involvement; more symmetrical; poor levodopa response; vascular risk factors ^[9]	Rarely confused but both can cause gait problems; vascular parkinsonism is in older patients
Normal pressure hydrocephalus (NPH)	Classical triad: frontal dementia, apraxic gait, urinary incontinence ^[15]; all ventricles enlarged on imaging	Gait abnormality can overlap, but NPH has characteristic triad and imaging

Must-Screen Rule for Young Movement Disorders

Copper studies (ceruloplasmin, 24h urinary copper) for Wilson's disease should be checked in any patient under 50 years presenting with unexplained movement disorder ^[9]^[16]. This is a treatable condition — missing it is medicolegally indefensible.

Wilson's disease can present with depression, neurosis, personality changes, psychosis ^[8]. These may precede neurological or hepatic features by months to years.

Differential	Key Distinguishing Features
Primary depressive disorder	No neurological signs; no liver disease; normal copper studies; responds to antidepressants
Schizophrenia / psychotic disorder	Typically presents in late teens/early 20s; no liver or neurological signs; family history of psychotic illness
Bipolar disorder	Episodic mood changes; no progressive neurological decline
Substance abuse	Relevant substance history; toxicology screen
Organic causes	Thyroid disease (TFT), SLE (ANA, anti-dsDNA), neurosyphilis (VDRL), Wilson's disease (copper studies), HIV

The key teaching point: always investigate for organic causes in any young patient with new-onset psychiatric symptoms, especially if accompanied by subtle neurological signs (tremor, dysarthria, gait change) or unexplained liver enzyme elevation. Copper studies for Wilson's disease should be part of the organic workup ^[16].

Coombs-negative haemolytic anaemia is a hallmark of Wilson's disease ^[3]^[7]. The differential of haemolytic anaemia is divided by the Coombs test result:

Category	Coombs Test	Examples	How Wilson's differs
Immune haemolysis	Positive	Warm AIHA, cold AIHA, drug-induced immune haemolysis, alloimmune (transfusion reaction, HDN)	Wilson's is Coombs negative — haemolysis is from direct copper toxicity, not antibodies ^[3]^[17]
Non-immune: Membrane defects	Negative	Hereditary spherocytosis, hereditary elliptocytosis	Family history; abnormal osmotic fragility; no liver disease
Non-immune: Enzyme defects	Negative	G6PD deficiency (common in HK and Southern Chinese)	Episodic, triggered by drugs/fava beans/infection; G6PD assay; no liver disease
Non-immune: Haemoglobinopathy	Negative	Sickle cell disease, thalassaemia	Hb electrophoresis; ethnic predisposition; no copper abnormality
Non-immune: Fragmentation	Negative	TTP, HUS, DIC, mechanical heart valves, HELLP	Schistocytes on blood film; thrombocytopenia; renal impairment (in TTP/HUS)
Non-immune: Infection	Negative	Malaria, Clostridium, Babesia	Travel history; blood film for parasites
Non-immune: PNH	Negative	Paroxysmal nocturnal haemoglobinuria	Flow cytometry (loss of CD55/CD59); pancytopenia; thrombosis
Non-immune: Toxin	Negative	Wilson's disease ^[3], copper sulfate poisoning, arsenic, lead	Wilson's: young patient + liver disease + low ceruloplasmin + elevated urine copper

Classic Exam Scenario – Fulminant Wilson's

Fulminant hepatic failure due to Wilson's has a very specific feature: young patients with no reason for fulminant liver failure, exclusion of all other common causes → only finding is low haemoglobin → Coombs-negative haemolytic anaemia ^[7]. The triad of ALF + Coombs-negative haemolysis + paradoxically low ALP in a young patient should scream Wilson's disease.

This is perhaps the most critical differential because it is life-threatening and Wilson's disease causing ALF has a specific management pathway (liver transplantation).

Differential	Key Distinguishing Features
Viral hepatitis (HAV, HBV, HEV)	Viral serology; exposure history; HBV common in HK ^[11]^[12]
Paracetamol overdose	Drug history; paracetamol level; characteristically sky-high transaminases (> 3000) with rapid fall
Autoimmune hepatitis	Autoantibodies; elevated IgG; may present fulminantly; can coexist with Wilson's ^[11]
Drug/toxin-induced	Exposure history; specific drug patterns
Wilson's disease	Young patient; Coombs-negative haemolytic anaemia; low ALP; AST:ALT > 2; low ceruloplasmin ^[3]^[4]^[7]
Pregnancy-related (AFLP, HELLP)	3rd trimester; thrombocytopenia (HELLP); microvesicular steatosis (AFLP)
Ischaemic hepatitis	Haemodynamic instability/shock preceding liver injury; massive LDH elevation ^[11]; rapid rise and fall of transaminases
Budd-Chiari syndrome	Hepatic vein thrombosis; prothrombotic states; ascites disproportionate to liver disease

A useful discriminating feature for Wilson's ALF: the AST:ALT ratio is usually > 2 ^[3] and ALP is paradoxically low (zinc-dependent enzyme; excess copper displaces zinc → reduced ALP activity). The ALP:total bilirubin ratio < 4 and AST:ALT ratio > 2.2 have been proposed as highly sensitive and specific for Wilson's disease as a cause of ALF.

6. Miscellaneous DDx by System

Other causes of acquired Fanconi syndrome: multiple myeloma (light chains), aminoglycosides, tenofovir, expired tetracyclines, heavy metals (lead, cadmium)
Differentiate by: copper studies, drug history, serum/urine protein electrophoresis

Wilson's disease is a recognised metabolic cause of CPPD crystal deposition disease, alongside haemochromatosis, hyperparathyroidism, hypomagnesaemia and hypophosphatasia ^[10]
In a young patient with chondrocalcinosis, always consider these secondary causes — CPPD in someone < 55 years old should trigger a metabolic screen

KF rings are NOT 100% specific for Wilson's — they can very rarely occur in primary biliary cholangitis (chronic cholestasis → copper retention → corneal deposition) and other cholestatic diseases
However, in the right clinical context (young patient, liver/neurological disease), KF rings are virtually pathognomonic

Feature	Wilson's	Viral hepatitis	AIH	NAFLD	Haemochromatosis	A1AT deficiency	IPD
Age	5–35y	Any	Young–middle-aged	Middle-aged	40–60y (M)	Young (liver); 30–50 (lung)	40–70y
Inheritance	AR	N/A	Polygenic	N/A	AR (HFE)	AR (SERPINA1)	Mostly sporadic
Ceruloplasmin	↓	Normal	Normal	Normal	Normal	Normal	Normal
Urine copper	↑	Normal	Normal	Normal	Normal	Normal	Normal
KF rings	+ (30–99%)	−	−	−	−	−	−
Haemolysis	Coombs −	Rare	Rare	No	No	No	No
LFT pattern	AST > ALT	ALT > AST (viral)	ALT > AST	ALT > AST	Mild elevation	Variable	Normal
Key test	Copper studies, Leipzig score	Viral serology	Autoantibodies, IgG	USS, metabolic screen	Ferritin, transferrin sat, HFE	α1-AT level, Pi typing	Clinical criteria, DaTscan

No single test is diagnostic ^[8] — diagnosis requires integration of clinical, biochemical, and sometimes histological and genetic data.

Diagnosis of Wilson's disease: No single test for diagnosis — serum copper, serum ceruloplasmin, 24-hour urinary copper excretion, liver biopsy with quantitative copper concentrations, slit-lamp examination for KF rings ^[8]. Family screening of first-degree relatives must be undertaken ^[8].

The approach is:

Suspect Wilson's in any patient < 40 years with unexplained liver disease, neuropsychiatric symptoms, or Coombs-negative haemolytic anaemia
Screen with serum ceruloplasmin, 24h urinary copper, slit-lamp exam for KF rings
Confirm with Leipzig scoring system ± liver biopsy (hepatic copper concentration ≥ 250 μg/g dry weight is diagnostic ^[4]) ± ATP7B mutation analysis
Exclude common mimics: viral serology, autoimmune screen, metabolic screen, drug history

High Yield Summary – Differential Diagnosis

Hepatic DDx: Viral hepatitis (especially HBV in HK), AIH, NAFLD, DILI, haemochromatosis, A1AT deficiency — all can cause chronic liver disease in young patients. Wilson's is distinguished by low ceruloplasmin, elevated urine copper, KF rings.
Neurological DDx: IPD, drug-induced parkinsonism, Huntington's, NBIA — Wilson's presents younger and has systemic features (liver disease, KF rings). Always check copper studies in young-onset movement disorders.
Haematological DDx: All causes of Coombs-negative haemolytic anaemia — Wilson's is distinguished by coexisting liver disease and copper metabolic derangement.
ALF DDx: Viral, paracetamol, AIH — Wilson's ALF has the classic triad: Coombs-negative haemolysis + low ALP + AST:ALT > 2.
Psychiatric DDx: Always investigate organic causes in young patients with new psychiatric symptoms — Wilson's is treatable.
No single test is diagnostic — use the Leipzig scoring system incorporating multiple parameters.
Family screening of first-degree relatives must be undertaken once a proband is identified.

Active Recall - Wilson's Disease Differential Diagnosis

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease) ^[3] Senior notes: Maksim Medicine Notes.pdf (Wilson's disease) ^[4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease – Diagnosis) ^[5] Lecture slides: GC 025. A jaundiced and incoherent patient liver failure.pdf ^[7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf ^[8] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Diagnosis slide) ^[9] Senior notes: Ryan Ho Neurology.pdf (Section 5.2 – Parkinsonism DDx) ^[10] Senior notes: Ryan Ho Rheumatology.pdf (CPPD crystal deposition disease) ^[11] Senior notes: Block A - Gastrointestinal Data Interpretation.pdf ^[12] Senior notes: Block A - Jaundice after raw oysters_ acute hepatitis.pdf ^[13] Senior notes: Maksim Surgery Notes.pdf (Hepatocellular carcinoma) ^[14] Senior notes: learning_points_output.txt (Neurology – Two Cases of Movement Disorders) ^[15] Senior notes: Ryan Ho Psychiatry.pdf (Dementia – NPH) ^[16] Senior notes: Ryan Ho Neurology.pdf (Dementia workup – copper studies) ^[17] Senior notes: Block A - Family history of anaemia_ inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf

Diagnostic Criteria, Algorithm and Investigations for Wilson's Disease

Before diving into the specifics, understand why Wilson's disease is notoriously hard to diagnose:

It is rare (1 in 30,000) — most clinicians will see very few cases in their career
It is protean — presentations span hepatology, neurology, psychiatry, haematology, nephrology
No single test is diagnostic ^[8] — each individual test has limitations (false positives and false negatives)
Ceruloplasmin can be normal in up to 10% of Wilson's patients ^[3]
KF rings can be absent in up to 50–70% of patients with purely hepatic disease ^[3]
Genetic testing does not have to be positive to reach a diagnosis because the hereditary pathway of Wilson's is very heterogeneous — not just ATP7B ^[7]

Therefore, diagnosis relies on a composite scoring system (Leipzig score) that integrates multiple parameters.

Suspect Wilson's disease if abnormal LFT with clinical presentations (e.g. dystonia, psychiatric symptoms) at young age ( < 30) ^[3]

Specific triggers to investigate:

Unexplained liver disease in a patient aged 5–40 years (any pattern: acute hepatitis, chronic hepatitis, cirrhosis, fulminant liver failure)
Young-onset movement disorder (parkinsonism, dystonia, tremor, chorea, ataxia, dysarthria)
New psychiatric symptoms in a young person with concurrent subtle neurological signs or liver enzyme elevation
Coombs-negative haemolytic anaemia, especially if accompanied by liver disease
Acute liver failure in a young patient with haemolysis and paradoxically low ALP
Unexplained Fanconi syndrome in a young person
Chondrocalcinosis or CPPD disease in a patient < 55 years (metabolic screen indicated)
Sibling of a known Wilson's disease patient (family screening)

Investigation Modalities — Detailed Breakdown

A. First-Line Screening Investigations

Parameter	Detail
What it is	Ceruloplasmin is an α2-glycoprotein synthesised in the liver that carries ~90% of circulating copper. It also has ferroxidase activity (oxidises Fe²⁺ → Fe³⁺ for loading onto transferrin)
Why it is low in Wilson's	ATP7B normally incorporates copper into apoceruloplasmin → holoceruloplasmin. Without copper incorporation, apoceruloplasmin (copper-free form) has a much shorter half-life → it is degraded rapidly → ↓ serum ceruloplasmin ^[1]^[2]^[3]
Diagnostic threshold	< 20 mg/dL (or < 0.2 g/L) is considered low ^[3]^[4]
Sensitivity	~85–90% — normal in up to 10% of patients ^[3]
False negatives (normal ceruloplasmin in Wilson's)	Ceruloplasmin is an acute-phase reactant → levels can be "falsely" normal/elevated in inflammation, infection, pregnancy, oestrogen use, malignancy
False positives (low ceruloplasmin without Wilson's)	Severe liver failure of any cause (reduced synthetic capacity), nephrotic syndrome (urinary protein loss), protein-losing enteropathy, malnutrition, aceruloplasminaemia (rare AR disorder of iron metabolism), heterozygous ATP7B carriers (~20% have mildly low levels), Menkes disease (X-linked copper deficiency)

Exam Pitfall – Ceruloplasmin

A normal ceruloplasmin does NOT exclude Wilson's disease. Conversely, a low ceruloplasmin does not confirm it. This is precisely why no single test is diagnostic ^[8] and why the Leipzig scoring system exists.

Parameter	Detail
Why it is elevated	Damaged hepatocytes release stored copper → increased free (non-ceruloplasmin-bound) copper in the blood → filtered by glomeruli → ↑ 24h urine Cu ^[2]^[3]
Diagnostic threshold	> 100 μg/day (> 1.6 μmol/day) in symptomatic patients is diagnostic when combined with other features ^[3]^[4]
In children	Threshold may be lower; > 40 μg/day is considered suspicious ^[4]
Penicillamine challenge test	If baseline urinary copper is equivocal, administer 500 mg D-penicillamine at start and again 12 hours later during the 24h collection. In Wilson's disease, urinary copper typically increases to > 1600 μg/day (> 25 μmol/day). This test is useful in paediatric patients with borderline results
False positives	Cholestatic liver disease (impaired biliary copper excretion → overflow into urine), autoimmune hepatitis, contamination of collection
False negatives	Very early disease (before significant hepatocyte damage), incomplete collection

Parameter	Detail
What they are	Copper deposits in Descemet's membrane of the cornea, appearing as golden-brown/greenish rings at the limbus ^[3]
Detection method	Slit-lamp examination — KF rings may NOT be visible to the naked eye, especially in dark-eyed individuals. Slit-lamp by an experienced ophthalmologist is mandatory ^[4]^[8]
Sensitivity	Present in 99% of patients with neuropsychiatric symptoms and 30–50% of patients with hepatic symptoms ^[3]
Specificity	High but NOT 100% — can rarely be seen in chronic cholestatic diseases (PBC, PSC) where prolonged copper retention occurs
Sunflower cataracts	Copper deposits in the lens — less common than KF rings; petal-like opacities on slit-lamp ^[4]

Slit-lamp examination for KF rings is one of the key diagnostic investigations listed by Prof. Yuen ^[8].

Parameter	Detail
Total serum copper	Paradoxically LOW in most Wilson's patients — because ~90% of serum copper is bound to ceruloplasmin, and ceruloplasmin is low. So total copper = ceruloplasmin-bound (low) + free copper (high), but the drop in ceruloplasmin-bound copper predominates
Free (non-ceruloplasmin-bound) copper	HIGH — this is the toxic fraction. Calculated as: Free Cu = Total Cu (μg/dL) − [3.15 × ceruloplasmin (mg/dL)]. Normal free copper is 10–15 μg/dL; in Wilson's disease it is typically > 25 μg/dL
Why this matters	Total serum copper can be misleadingly low; the clinically relevant measurement is free copper, which reflects the copper causing tissue damage

B. Second-Line / Confirmatory Investigations

Liver biopsy is the GOLD standard for diagnosis ^[4]

Parameter	Detail
Why it is the gold standard	Directly measures copper content in the liver — the primary site of accumulation
Diagnostic threshold	Hepatic copper concentration ≥ 250 μg/g of dry weight is diagnostic ^[4]
Exclusion threshold	Hepatic copper concentration < 50 μg/g of dry weight effectively excludes Wilson's ^[4]
Grey zone	50–250 μg/g: molecular genetic testing is indicated if histology reveals evidence of active liver disease ^[4]
Histological features	Similar to autoimmune hepatitis and non-alcoholic steatohepatitis including fatty infiltration within hepatocytes, glycogen inclusions within nuclei, and portal fibrosis ^[4]. Special stains: rhodanine or rubeanic acid stain for copper; orcein stain for copper-associated protein. Note: these stains have low sensitivity — quantitative measurement is essential
Limitations	Sampling variation may lead to false-negative results and hepatic copper concentration should always be evaluated in the context of other diagnostic criteria ^[4]; contraindicated in severe coagulopathy (e.g., fulminant liver failure — precisely when you need it most)

Key Concept – Why Biopsy Histology Can Be Misleading

Histological features are similar to autoimmune hepatitis and NASH ^[4]. Without quantitative copper measurement, the biopsy alone may lead to a misdiagnosis of AIH or NASH. Always request quantitative hepatic copper concentration alongside histology.

Parameter	Detail
When indicated	When the diagnosis remains unclear despite liver biopsy, or to aid screening of family members when the mutation in the proband is known ^[4]
NOT for initial diagnosis	Abundance of disease-specific mutations complicates genetic testing. The genetic component of the disease is heterogeneous such that there are presence of other mutation types causing Wilson's disease that are not currently known ^[4]^[7]
For family screening	Family screening of siblings should begin with mutation analysis for ATP7B mutation if the identified patient (proband) has been tested ^[4]
Practical point	In East Asian / Chinese populations, R778L is the most common mutation (vs H1069Q in Europeans). Targeted panels may miss rare/novel mutations → full gene sequencing may be needed

Genetic test does not have to be positive to reach a diagnosis → with compatible clinical and history, you can still diagnose ^[7]. This is a critical exam point: a negative genetic test does NOT exclude Wilson's disease.

C. Supportive / Ancillary Investigations

Finding	Interpretation
Coombs-negative haemolytic anaemia	Associated with acute liver failure in Wilson's disease but can occur episodically independent of liver failure. Results from effects of excess copper ions on the RBC membrane in the circulation due to hepatic copper release following cellular necrosis ^[4]
Reticulocytosis	Bone marrow compensatory response to haemolysis
Thrombocytopenia	Hypersplenism due to portal hypertension in patients with liver cirrhosis ^[4]
Leucopenia	Hypersplenism
Blood film	May show spherocytes (non-specific); schistocytes are NOT expected (this is not microangiopathic)

Finding	Interpretation
Negative	Confirms haemolysis is NOT immune-mediated — this is direct copper toxicity to RBC membranes

Finding	Interpretation
↑ AST and ALT (aminotransferases)	Reflect hepatocellular damage from copper accumulation ^[4]
AST is usually higher than ALT (ratio > 2) in patients with Wilson's disease	This is unusual — most hepatocellular diseases (e.g., viral hepatitis) have ALT > AST. The 4 cases where AST > ALT include: Alcoholic hepatitis, Cirrhosis (any cause), Wilson's disease, and ischaemic/cardiac hepatitis ^[11]. The reason AST > ALT in Wilson's relates to the degree of mitochondrial damage (AST has a mitochondrial isoform released in more severe injury) and possibly to associated cirrhosis
Low ALP	Paradoxically low in fulminant Wilson's — ALP is a zinc-dependent metalloenzyme; excess copper displaces zinc, reducing enzyme activity. ALP:bilirubin ratio < 4 is a useful diagnostic clue in ALF
↑ Bilirubin	Combination of hepatocellular damage + haemolysis (unconjugated fraction from haemolysis, conjugated from liver dysfunction)
Low albumin	Impaired hepatic synthetic function (if chronic disease/cirrhosis)

Finding	Interpretation
Coagulopathy	Secondary to cirrhosis or acute liver failure ^[4] — impaired hepatic synthesis of clotting factors (II, VII, IX, X)
Elevated INR	Important for prognostication and transplant listing (King's College criteria, New Wilson Index)

Finding	Interpretation
Rule out other differential diagnosis including chronic viral hepatitis ^[4]	HBsAg, anti-HCV IgG, and if positive: HBV DNA, HBeAg, anti-HBc IgM (for HBV); HCV RNA (for HCV). Essential in HK where HBV is endemic

Investigation	Finding	Interpretation
LDH	Elevated	Reflects haemolysis (LDH released from lysed RBCs)
Haptoglobin	Low	Consumed by binding free haemoglobin released during haemolysis
Uric acid	Low	Fanconi syndrome → renal uric acid wasting
Phosphate	Low	Fanconi syndrome → phosphaturia
ABG	Normal anion gap metabolic acidosis	Fanconi syndrome → proximal RTA (type 2) — bicarbonate wasting
Urinalysis	Glycosuria, aminoaciduria, phosphaturia	Fanconi syndrome — generalised proximal tubule transport defect
Serum urea	May be low	Impaired hepatic urea cycle in liver failure

D. Radiological Investigations

Finding	Interpretation
Hepatic steatosis in chronic hepatitis	Copper-induced hepatocyte fat accumulation ^[4]
Small nodular liver in liver cirrhosis	End-stage fibrotic liver ^[4]
Splenomegaly in liver cirrhosis	Portal hypertension → splenic congestion ^[4]
Ascites	Decompensated cirrhosis

Finding	Interpretation
MOST common finding is increased T2 signal intensity in the basal ganglia	Copper deposition → oedema, gliosis, neuronal loss in putamen, caudate, thalamus ^[4]
"Face of giant panda sign"	Hyperintense signal in the tegmentum of midbrain especially around red nucleus which has normal hypointensity ^[4] — the normal dark red nucleus surrounded by bright signal creates the "eyes" of the panda face. This is a classic but NOT always present sign
T1 hyperintensity	May be seen in globus pallidus due to copper/manganese deposition or chronic hepatic encephalopathy
Cortical and cerebellar atrophy	In advanced disease

MRI brain: "face of giant panda" in midbrain ^[3]

Investigation	Finding
MRI liver	Can show iron and copper co-deposition; elastography for fibrosis staging
FibroScan (transient elastography)	Non-invasive fibrosis assessment — useful for monitoring rather than initial diagnosis
X-ray joints	Chondrocalcinosis, premature degenerative changes

Diagnostic Criteria

This practical algorithm from the senior notes ^[4] integrates the three core screening tests:

Serum Ceruloplasmin	KF Ring	24h Urine Copper	Result
Low ( < 20 mg/dL)	Present	> 40 μg	Diagnostic
Low ( < 20 mg/dL)	Present	≤ 40 μg	Liver biopsy OR genetic testing required
Low ( < 20 mg/dL)	Absent	> 100 μg	Diagnostic
Low ( < 20 mg/dL)	Absent	≤ 100 μg	Liver biopsy OR genetic testing required
Normal (≥ 20 mg/dL)	Present	Any	Liver biopsy OR genetic testing required
Normal (≥ 20 mg/dL)	Absent	> 40 μg	Liver biopsy OR genetic testing required
Normal (≥ 20 mg/dL)	Absent	≤ 40 μg	Diagnosis EXCLUDED

GC High Yield – Diagnostic Table

This diagnostic combination table is likely directly testable on HKUMed exams. The key principle: you need at least two abnormal tests to diagnose, or if only one is abnormal, proceed to liver biopsy or genetic testing. The only scenario where diagnosis is excluded is when ceruloplasmin is normal, KF rings are absent, AND urine copper is ≤ 40 μg.

The Leipzig score ^[3] is the internationally adopted semi-quantitative scoring system for Wilson's disease diagnosis. It was developed at the 8th International Meeting on Wilson's disease in Leipzig (2001) and remains the EASL/AASLD recommended tool.

Parameter	Finding	Score
KF rings	Present	+2
	Absent	0
Neuropsychiatric symptoms	Severe	+2
	Mild	+1
	Absent	0
Coombs-negative haemolytic anaemia	Present	+1
	Absent	0
24h urinary copper	> 2× ULN (> 100 μg)	+2
	1–2× ULN (40–100 μg)	+1
	Normal ( < 40 μg)	0
Liver copper (quantitative)	> 250 μg/g (> 4 μmol/g)	+2
	50–250 μg/g	+1
	Normal ( < 50 μg/g)	−1
Rhodanine-positive hepatocytes	Present	+1
	Absent	0
Serum ceruloplasmin	< 10 mg/dL	+2
	10–20 mg/dL	+1
	> 20 mg/dL	0
Mutation analysis	Two disease-causing mutations detected	+4
	One disease-causing mutation detected	+1
	No mutations detected	0

Interpretation:

Total Score	Interpretation
≥ 4	Diagnosis established
3	Possible — more tests needed
≤ 2	Diagnosis unlikely

Leipzig Score – Exam Favourite

You do NOT need to memorise every point value, but you should know the principle: it is a composite score integrating clinical (KF rings, neuropsych, haemolysis), biochemical (ceruloplasmin, urine copper), histological (liver copper), and genetic (ATP7B mutation) parameters. A score ≥ 4 establishes the diagnosis. Finding two mutations on ATP7B alone gives +4 — immediately diagnostic.

When a young patient presents with acute liver failure and the question is "Is this Wilson's?", specific biochemical ratios are highly discriminating:

Parameter	Cut-off	Sensitivity/Specificity
ALP : total bilirubin ratio	< 4	Sensitivity 94%, Specificity 96%
AST : ALT ratio	> 2.2	Sensitivity 94%, Specificity 86%

If BOTH ratios are met → sensitivity 100%, specificity 100% for Wilson's as the cause of ALF (in the original derivation cohort). These are sometimes called the Berman criteria.

Additionally, the New Wilson Index (NWI) / Revised King's Score is used for prognostication and transplant listing in fulminant Wilson's — incorporates serum bilirubin, INR, AST, WCC, and albumin. A score ≥ 11 predicts death without liver transplant.

Family screening of first-degree relatives must be undertaken ^[8] once a diagnosis is established. This is explicitly stated in Prof. Yuen's lecture slide.

Once a proband (index case) is diagnosed:

All first-degree relatives (especially siblings — 25% risk if both parents are carriers) should be screened
Screening includes: serum ceruloplasmin, 24h urinary copper, LFT, slit-lamp examination
Family screening of siblings should begin with mutation analysis for ATP7B mutation if the identified patient (proband) has been tested ^[4] — this is the most efficient approach when the proband's mutations are known
Asymptomatic affected siblings should be treated (usually with zinc maintenance therapy) to prevent disease progression

Investigation	Key Finding in Wilson's	Sensitivity	Limitations
Serum ceruloplasmin	< 20 mg/dL	~85–90%	Normal in 10%; affected by inflammation, pregnancy, oestrogen
24h urine copper	> 100 μg (symptomatic)	~80–90%	Collection errors; equivocal in early disease
Slit-lamp	KF rings	99% neuro; 30–50% hepatic	Not visible to naked eye; rare in other cholestatic disease
Liver biopsy	Hepatic Cu ≥ 250 μg/g dry wt	GOLD standard	Sampling error; contraindicated in coagulopathy
Free serum copper	> 25 μg/dL	Good	Calculated, depends on accurate ceruloplasmin
MRI brain	T2 hyperintensity basal ganglia; "face of giant panda"	High in neurological Wilson's	Not specific; absent in hepatic-only
ATP7B mutation analysis	2 pathogenic mutations	High if found	> 200 mutations; many private; may miss novel variants
Leipzig score	≥ 4	Best composite accuracy	Requires multiple tests

GC High Yield – Prof. Yuen's Lecture Points on Diagnosis

No single test for diagnosis. The key diagnostic investigations are:

Serum copper
Serum ceruloplasmin
24-hour urinary copper excretion
Liver biopsy with quantitative copper concentrations
Slit-lamp examination for KF rings
Family screening of first-degree relatives must be undertaken ^[8]

These points are directly from the GC teaching clinic lecture and represent the expected exam answer framework.

High Yield Summary – Diagnosis

No single test is diagnostic — use the Leipzig scoring system (≥ 4 = diagnosed)
Three core screening tests: ceruloplasmin (< 20 mg/dL), 24h urine copper (> 100 μg), slit-lamp for KF rings
Liver biopsy is the GOLD standard — hepatic Cu ≥ 250 μg/g dry weight is diagnostic, < 50 excludes
Histology mimics AIH and NASH — always request quantitative copper alongside histology
ATP7B genetic testing is NOT used for initial diagnosis due to genetic heterogeneity; reserved for unclear cases and family screening
AST > ALT (ratio > 2) is a characteristic LFT pattern; low ALP is a clue in fulminant Wilson's
Fulminant Wilson's ALF clues: Coombs-negative haemolysis + ALP:bilirubin < 4 + AST:ALT > 2.2
Family screening of first-degree relatives must be undertaken — begin with mutation analysis if proband's mutations are known
MRI brain: T2 hyperintensity in basal ganglia; "face of giant panda sign" in midbrain
KF rings present in 99% with neuropsychiatric disease but only 30–50% with hepatic disease

Active Recall - Wilson's Disease Diagnosis

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease) ^[2] Senior notes: Ryan Ho GI.pdf (Section 4.5.3 – Wilson's Disease) ^[3] Senior notes: Maksim Medicine Notes.pdf (Wilson's disease) ^[4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease – Diagnosis) ^[7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf ^[8] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Diagnosis slide) ^[11] Senior notes: Block A - Gastrointestinal Data Interpretation.pdf ^[18] Senior notes: Ryan Ho Chemical Path.pdf (Section 8.2 – Investigations of IEM)

Management of Wilson's Disease

Wilson's disease management rests on a simple concept: copper is accumulating because the body cannot excrete it, so we must either remove the excess copper (chelation), block its absorption (zinc), or replace the defective liver (transplantation). Treatment is lifelong — discontinuation leads to relapse and can be fatal.

The management strategy depends on the clinical presentation and disease severity:

Symptomatic patients (hepatic, neurological, or both) → copper chelation therapy to de-copper the body
Asymptomatic patients / maintenance → zinc therapy to prevent copper re-accumulation
Acute liver failure → rapid copper removal + consideration of liver transplantation
Decompensated cirrhosis refractory to medical therapy → liver transplantation
All patients → genetic counselling, family screening, dietary advice, lifelong monitoring

Pharmacological Treatment — Detailed Breakdown

There are two categories of drugs: copper chelators (remove accumulated copper) and copper absorption inhibitors (prevent further uptake from the gut).

A. Copper Chelators

The concept of chelation: "chelator" comes from the Greek word chele meaning "claw" — these drugs literally grab copper ions and form soluble complexes that can be excreted in urine.

"Penicillamine" — derived from penicillin (it is a degradation product), but it is NOT an antibiotic. The "-amine" suffix reflects its amino acid-like structure.

Parameter	Detail
Mechanism	Chelates free copper → forms a soluble penicillamine-copper complex → excreted renally in urine
Indication	First-line chelator due to lower cost, but similar efficacy as trientine ^[3]. Symptomatic hepatic Wilson's disease; historically also used in neurological disease but trientine is now preferred for neurological presentations (see below)
Dose	Start at 250–500 mg/day, titrate up to 1–1.5 g/day in 2–4 divided doses. Take on an empty stomach (1 hour before or 2 hours after meals) — food reduces absorption
Must co-prescribe	Given with vitamin B6 (pyridoxine) ^[3] — penicillamine is a pyridoxine antagonist; without supplementation, patients can develop B6 deficiency (peripheral neuropathy, sideroblastic anaemia)
Monitoring	24h urine copper (should initially rise with treatment, then fall as body stores deplete); ceruloplasmin; LFT; CBC; urinalysis (for proteinuria)

Side effects — this is a high-yield exam list:

Side Effect	Mechanism
Initial worsening of neurological symptoms	Penicillamine causes worsened neurological symptoms in the first few days — Patient is used to copper in brain, but once penicillamine is given, they lose copper, body is not used to the change, may exacerbate the neuro symptoms ^[7]. This is due to rapid mobilisation of hepatic copper into the bloodstream before it can be excreted → transient spike in free copper → paradoxical worsening. Occurs in up to 50% of patients with neurological disease
Nephrotoxicity	Immune complex deposition → membranous nephropathy → proteinuria → nephrotic syndrome. Monitor with regular urinalysis ^[3]
Myasthenia gravis (MG)	Drug-induced autoimmune phenomenon — penicillamine can induce anti-acetylcholine receptor antibodies ^[3]
Drug-induced lupus (DIL)	Penicillamine-induced autoimmune phenomenon — ANA positive, anti-histone antibodies ^[3]
Bone marrow suppression	Aplastic anaemia, thrombocytopenia, agranulocytosis — monitor CBC
Skin reactions	Elastosis perforans serpiginosa (abnormal elastic tissue), pemphigus, rash
GI upset	Nausea, anorexia — take on empty stomach
Taste disturbance	Dysgeusia — usually transient

Critical Exam Point – Neurological Worsening with Penicillamine

Penicillamine causes worsened neurological symptoms in the first few days ^[7]. This is the single most important reason why trientine is preferred over penicillamine in patients presenting with neurological disease. The worsening can be irreversible. If you must use penicillamine, start at a very low dose and titrate slowly.

Contraindications:

Previous penicillamine hypersensitivity
History of penicillamine-induced aplastic anaemia or agranulocytosis
Lupus nephritis or pre-existing renal disease (relative)
Caution in penicillin allergy (cross-reactivity is rare but theoretically possible due to structural relationship)

"Trientine" — "tri-" = three, "en" = from ethylene, "-tine" = amine; it has three ethylene diamine groups that form a cage to trap copper.

Parameter	Detail
Mechanism	Alternative copper chelator — chelates copper in the GI tract (reducing absorption) and in the circulation → excreted renally
Indication	Similar efficacy as penicillamine ^[3]. Preferred over penicillamine for neurological Wilson's disease because it causes less neurological worsening. Also used when penicillamine is not tolerated (side effects)
Dose	750–1500 mg/day in 2–3 divided doses, on an empty stomach
Advantage	Fewer and less severe side effects than penicillamine; lower risk of initial neurological deterioration

Side effects:

Side Effect	Mechanism
Chelates iron and zinc to form ineffective complexes	Separate by 1 hour when taking iron or zinc supplements ^[3] — if taken together, trientine binds these metals instead of copper, reducing efficacy
GI upset	Less common than penicillamine
Sideroblastic anaemia	Due to iron chelation (rare)
Pancytopenia	Rare

Contraindications:

Known hypersensitivity
Concurrent iron supplementation (relative — separate timing)

Feature	Penicillamine	Trientine
Efficacy	Similar ^[3]	Similar ^[3]
Cost	Lower cost — preferred for this reason ^[3]	More expensive
Initial neuro worsening	Up to 50% — significant risk ^[7]	Lower risk — preferred for neurological disease
Must co-prescribe	Vitamin B6 ^[3]	No B6 needed
Autoimmune side effects	MG, lupus, nephrotoxicity	Much rarer
Drug interactions	Fewer	Chelates iron/zinc — separate by 1 hour ^[3]

3. Oral Zinc (Zinc acetate, Zinc sulfate)

"Zinc" — the mechanism is beautifully logical and worth understanding from first principles.

Parameter	Detail
Mechanism	Zinc induces metallothionein synthesis in enterocytes. Metallothionein is a cysteine-rich protein that has an extremely high affinity for copper. When metallothionein binds copper in the enterocyte, the copper becomes trapped inside the cell. When the enterocyte is naturally shed (enterocyte turnover every 3–5 days), the copper-metallothionein complex is lost in the faeces → net negative copper balance. Zinc also induces metallothionein in hepatocytes, binding intracellular copper and rendering it non-toxic
Indication	Maintenance treatment in asymptomatic patients ^[3]; also used as maintenance after initial de-coppering with a chelator; can be used in presymptomatic patients identified by family screening; suitable for pregnant patients (safer profile)
Dose	150 mg elemental zinc daily in 3 divided doses (e.g., zinc acetate 50 mg TDS), taken on an empty stomach (at least 1 hour before meals)
NOT suitable as sole initial therapy in symptomatic patients	Too slow-acting — it takes weeks to months to build up sufficient metallothionein; meanwhile copper continues to damage organs. Use chelator first to rapidly de-copper, then switch to zinc for maintenance

Side effects:

Side Effect	Mechanism
GI upset	Main side effect ^[3] — nausea, abdominal pain, metallic taste. Zinc acetate may be better tolerated than zinc sulfate
Elevated lipase/amylase	Usually asymptomatic; rarely clinically significant pancreatitis

Contraindications:

Hypersensitivity to zinc salts
Should NOT be taken concurrently with copper chelators (zinc induces metallothionein which would then chelate the chelator-copper complex before it can be excreted) — separate by at least 1–2 hours if used together during transition periods

Zinc – The Elegant Mechanism

Think of zinc therapy as "setting a trap in the gut." Zinc upregulates metallothionein in enterocytes → metallothionein preferentially binds dietary copper → copper is trapped in the enterocyte → when the enterocyte dies and is shed into the gut lumen (normal turnover), copper is lost in the stool. The body never absorbs the copper in the first place. This is why zinc is ideal for maintenance but too slow for acute treatment.

Clinical Scenario	First-Line Treatment	Rationale
Symptomatic hepatic disease	Penicillamine (+ vitamin B6) or Trientine	Need rapid de-coppering; penicillamine preferred for cost; trientine if intolerant ^[3]
Neurological / psychiatric disease	Trientine preferred	Lower risk of initial neurological worsening than penicillamine ^[7]
Asymptomatic / presymptomatic	Oral Zinc	Maintenance treatment in asymptomatic patients ^[3]; prevents copper accumulation without aggressive chelation
Maintenance after de-coppering	Oral Zinc ± low-dose chelator	Long-term prevention of re-accumulation
Pregnancy	Oral Zinc	Safest profile; chelators are teratogenic (especially penicillamine — associated with cutis laxa and connective tissue defects in newborn). Dose may need to be adjusted
Paediatric / family screening	Oral Zinc or low-dose Trientine	Depending on age and disease status

Non-Pharmacological Management

Measure	Detail
Avoid high-copper foods	Shellfish (especially oysters, lobster), liver and organ meats, chocolate, nuts (especially cashews), mushrooms, soy products, dried fruits
Safe foods	Most vegetables, fruits, grains, rice, chicken, fish
Water	Check household water copper content — copper piping can leach copper into water; use bottled water if copper levels are high
Practical importance	Diet alone is NEVER sufficient — always requires pharmacotherapy. Dietary measures are adjunctive

Alcohol — direct hepatotoxin that accelerates liver damage in an already compromised organ
Paracetamol excess — avoid high doses
Hepatotoxic drugs — check any new medication for hepatotoxicity

AR inheritance → 25% risk to siblings
Carrier testing for partners of patients with Wilson's disease
Prenatal diagnosis possible if both mutations in the family are known

Family screening of first-degree relatives must be undertaken ^[8]

All siblings and children of the proband should be screened
Screening: ceruloplasmin, 24h urine copper, LFT, slit-lamp examination
Family screening of siblings should begin with mutation analysis for ATP7B mutation if the identified patient (proband) has been tested ^[4]

Management of Acute Liver Failure Due to Wilson's Disease

This is a medical emergency. The approach combines rapid copper removal with consideration for liver transplantation.

Method	Mechanism
Haemodialysis	Rapid copper removal ^[3] — dialysis directly removes free copper from the circulation. Also corrects electrolyte and acid-base disturbances
Plasmapheresis / plasma exchange	Removes copper-containing plasma proteins and free copper; also removes inflammatory cytokines
Albumin dialysis (MARS — Molecular Adsorbents Recirculating System)	Experimental — removes albumin-bound toxins including copper

Standard acute liver failure management principles apply:

Airway protection — patients may develop hepatic encephalopathy
Haemodynamic support — fluid resuscitation, vasopressors if needed
Coagulopathy management — FFP / cryoprecipitate only if actively bleeding or for procedures (avoid "correcting" INR unnecessarily as it is a prognostic marker)
Cerebral oedema monitoring — ICP monitoring in grade III/IV encephalopathy
Infection surveillance — sepsis is a major cause of death in ALF
Renal support — renal replacement therapy if oliguric/anuric (hepatorenal syndrome + direct copper nephrotoxicity)
Nutrition — enteral feeding preferred; avoid protein restriction (this is outdated)

Liver transplantation — effective cure ^[8]^[19]

Parameter	Detail
Why it is curative	Liver transplantation provides normal ATP7B in the graft liver ^[1] — the new liver has functional copper transport machinery, so copper metabolism normalises. It is essentially a form of gene therapy at the organ level
Indications	Indicated for fulminant hepatic failure: coagulopathy and encephalopathy, Coombs-negative haemolytic anaemia, rapid deterioration within 8 weeks from onset of illness ^[1]^[8]^[19]
	Indicated for those refractory to medical therapy — i.e., decompensated cirrhosis that fails to respond to chelation ^[8]^[19]
NOT indicated	Not indicated if only for neurologic disease ^[19] — this is explicitly stated in Prof. Yuen's lecture. The rationale: liver transplant carries significant surgical morbidity/mortality, and neurological disease can often be managed medically. However, this remains controversial (see below)
Prognostic scoring	New Wilson Index (Revised King's Score) — incorporates bilirubin, INR, AST, WCC, albumin. Score ≥ 11 predicts death without transplant

GC High Yield – Prof. Yuen's Lecture Points on Treatment

Treatment of Wilson's Disease:

Liver transplantation — effective cure
Indicated for fulminant hepatic failure:
- Coagulopathy and encephalopathy
- Coombs-negative haemolytic anaemia
- Rapid deterioration within 8 weeks from onset of illness
Indicated for those refractory to medical therapy
Not indicated if only for neurologic disease ^[19]

These are directly from the GC teaching clinic lecture slide and represent expected exam content.

The standard teaching is not indicated if only for neurologic disease ^[19]
However, emerging evidence suggests that liver transplant can improve and even reverse neurological symptoms in some patients, because normalisation of copper metabolism prevents ongoing brain deposition
Liver transplantation has been demonstrated to improve neurological symptomatology and can act as a form of gene therapy ^[1]
Current consensus (EASL 2012/AASLD 2022 guidelines): liver transplantation is NOT recommended solely for neurological disease, but may be considered in selected cases where neurological disease is severe and refractory to medical chelation therapy
This is an evolving area — for exam purposes, state the standard teaching first, then mention the controversy

Parameter	Frequency	Purpose
24h urinary copper	Every 3–6 months initially, then annually	Assess de-coppering progress; on chelation, expect initial rise then gradual fall; on zinc, should remain < 75 μg/day
Serum ceruloplasmin	Every 6–12 months	Baseline marker; may rise slightly with treatment
Free (non-CP-bound) copper	Every 3–6 months	Target < 15 μg/dL on maintenance
LFT	Every 3–6 months	Monitor liver disease activity; assess response
CBC	Every 1–3 months (penicillamine); less frequent (trientine/zinc)	Monitor for bone marrow suppression (penicillamine)
Urinalysis	Every 1–3 months (penicillamine)	Monitor for proteinuria (nephrotoxicity)
Slit-lamp exam	Annually	KF rings should fade with effective treatment
Clinical neurological assessment	Every visit	Detect improvement or deterioration
Compliance assessment	Every visit	Non-compliance is a major cause of treatment failure and can be fatal

Non-Compliance = Death

Non-compliance with chelation/zinc therapy is the single most dangerous pitfall. Patients who stop treatment — even after years of stability — will re-accumulate copper and can develop rapidly progressive liver failure or neurological deterioration that may be irreversible. Prognosis is excellent if treated: 86% 5-year survival; ~30% die from hepatic complications if untreated ^[1]. Adolescents are particularly at risk for non-compliance.

Scenario	Outcome
Treated, compliant	Excellent: 86% 5-year survival ^[1]; normal life expectancy is achievable
Untreated	Universally fatal; ~30% die from hepatic complications ^[1]
Post-transplant	> 80% 5-year survival; copper metabolism normalises; KF rings fade
Neurological disease	Hepatic symptoms respond faster than neurological symptoms; neurological improvement may take months to years and may be incomplete in advanced disease

Treatment	Mechanism	Indication	Key Side Effects	Key Points
Penicillamine	Cu chelation → renal excretion	Symptomatic hepatic disease; 1st-line by cost	Initial neuro worsening, nephrotoxicity, MG, DIL ^[3]	Give with vitamin B6 ^[3]
Trientine	Cu chelation → renal excretion	Neurological disease; penicillamine-intolerant	Chelates iron/zinc ^[3]; GI upset	Separate from Fe/Zn by 1 hour ^[3]
Oral Zinc	Induces metallothionein → blocks gut Cu absorption	Maintenance in asymptomatic patients ^[3]; pregnancy	GI upset ^[3]	Too slow for initial Rx of symptomatic disease
Haemodialysis	Rapid Cu removal ^[3]	Acute liver failure	Standard dialysis risks	Bridge to transplant
Liver transplant	Effective cure — provides normal ATP7B ^[1]^[19]	Fulminant liver failure; refractory decompensated cirrhosis ^[19]	Surgical and immunosuppression risks	Not indicated if only for neurologic disease ^[19]

High Yield Summary – Management

Treatment is lifelong — discontinuation leads to relapse and death
Symptomatic patients → copper chelator (penicillamine or trientine) for initial de-coppering
Penicillamine: lower cost, preferred first-line; co-prescribe vitamin B6; S/E include initial neurological worsening, nephrotoxicity, MG, drug-induced lupus ^[3]^[7]
Trientine: preferred for neurological disease because penicillamine causes initial worsening; chelates iron/zinc → separate by 1 hour ^[3]
Oral Zinc: maintenance treatment in asymptomatic patients ^[3]; mechanism = induces metallothionein in enterocytes
Liver transplantation = effective cure; indicated for fulminant hepatic failure (coagulopathy + encephalopathy + Coombs-negative haemolysis + rapid deterioration within 8 weeks) and refractory decompensated cirrhosis ^[19]
Liver transplantation NOT indicated if only for neurologic disease ^[19]
Haemodialysis for rapid copper removal in acute liver failure ^[3]
Genetic counselling and family screening of first-degree relatives are mandatory ^[3]^[8]
Prognosis: excellent if treated (86% 5-year survival); universally fatal if untreated ^[1]

Active Recall - Wilson's Disease Management

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease, Management) ^[3] Senior notes: Maksim Medicine Notes.pdf (Wilson's disease – Management) ^[4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease – Diagnosis and Family Screening) ^[7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf ^[8] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Diagnosis slide) ^[19] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Treatment slide)

Complications of Wilson's Disease

The complications of Wilson's disease arise from two fundamental processes:

Direct copper toxicity to the organs where copper accumulates (liver, brain, kidneys, blood, eyes, joints, heart)
Secondary consequences of end-organ damage, particularly the complications of liver cirrhosis and portal hypertension — these are shared with cirrhosis of any cause but deserve specific attention because they are the leading cause of morbidity and mortality in Wilson's disease

Additionally, there are treatment-related complications that are important to recognise.

Prognosis: excellent if treated, 86% 5-year survival; ~30% die from hepatic complications if untreated ^[1]

A. Hepatic Complications

Wilson's disease progresses through a spectrum of liver injury. Once cirrhosis develops, the patient faces all of the complications of cirrhosis — identical to cirrhosis from any aetiology.

GC High Yield – Complications of Cirrhosis (One-Slide Overview)

From the GC 026 lecture slide on cirrhosis ^[20], the complications framework is:

Compensated cirrhosis (Child A):

Variceal disease
Portal vein thrombosis
HCC

Decompensated cirrhosis (Child B/C):

Variceal disease
Portal vein thrombosis
Ascites
SBP
Hepatic hydrothorax
Hepatorenal syndrome

Other complications (both):

HE (hepatic encephalopathy)
HCC
Liver failure
Infections
Bleeding tendency

This framework applies to Wilson's disease-related cirrhosis just as it does to any other cause.

Aspect	Detail
Frequency	Occurs in 8–12% of Wilson's disease patients ^[1]
Mechanism	Massive hepatocyte necrosis from copper overload → sudden release of large quantities of stored copper into the bloodstream → multi-organ toxicity
Key features	Coagulopathy and encephalopathy, Coombs-negative haemolytic anaemia, rapid deterioration within 8 weeks from onset of illness ^[1]^[19]
Why haemolysis occurs	The massive copper release deposits on RBC membranes → oxidative damage → intravascular haemolysis (Coombs-negative because it is not immune-mediated)
Paradoxically low ALP	ALP is a zinc-dependent metalloenzyme; excess copper displaces zinc → reduced enzyme activity
Prognosis without transplant	Near-universally fatal; New Wilson Index ≥ 11 predicts death without transplant
Management	Rapid copper removal (haemodialysis, plasmapheresis) → liver transplantation if criteria met ^[1]^[19]

Fulminant hepatic failure due to Wilson's has a very specific feature: young patients with no reason for fulminant liver failure, exclusion of all other common causes → only finding is low haemoglobin → Coombs-negative haemolytic anaemia ^[7]

2. Cirrhosis and Portal Hypertension

Present in ~35–45% of patients at time of diagnosis ^[1]. Once cirrhosis is established, all portal hypertension-related complications ensue. Let me walk through each:

Aspect	Detail
Mechanism	Portal hypertension (pressure > 10 mmHg in portal system) → blood seeks alternative routes (portosystemic anastomoses) → oesophageal and gastric varices develop → thin-walled veins under high pressure → rupture → massive upper GI haemorrhage
Presentation	Haematemesis (coffee-ground or frank blood), melaena, haemodynamic instability
Why it matters	Life-threatening; mortality per episode ~15–20%
Management	Resuscitation, IV octreotide/terlipressin, urgent OGD with band ligation, secondary prophylaxis with non-selective beta-blockers

Aspect	Detail
Mechanism	Portal hypertension → ↑ splanchnic hydrostatic pressure + arterial vasodilation → activation of RAAS and sympathetic nervous system → Na⁺/water retention. Combined with ↓ albumin (impaired hepatic synthesis) → ↓ plasma oncotic pressure → fluid transudation into peritoneal cavity
Clinical sign	Shifting dullness, fluid thrill; USS for small volumes
Management	Salt restriction, diuretics (spironolactone ± furosemide), therapeutic paracentesis with albumin replacement

Aspect	Detail
Mechanism	Bacterial translocation from gut to ascitic fluid (impaired gut barrier + portal hypertension) + reduced opsonic activity of ascitic fluid (low complement, low protein) + impaired reticuloendothelial function in liver failure → infection of ascitic fluid without obvious intra-abdominal source
Presentation	Fever, abdominal pain, worsening ascites, encephalopathy; can be insidious
Diagnosis	Ascitic fluid PMN > 250/mm³
Management	IV third-generation cephalosporin (e.g. ceftriaxone); secondary prophylaxis with oral norfloxacin/ciprofloxacin

Aspect	Detail
Mechanism	Ascitic fluid tracks through diaphragmatic defects (usually right-sided) into the pleural space
Presentation	Dyspnoea, right-sided pleural effusion in a cirrhotic patient without primary cardiopulmonary disease

Aspect	Detail
Mechanism	Severe portal hypertension → splanchnic vasodilation → effective hypovolaemia → maximal RAAS/sympathetic activation → profound renal vasoconstriction → functional renal failure (kidneys are structurally normal)
Types	Type 1 (rapidly progressive, doubling of creatinine in < 2 weeks) and Type 2 (more gradual, a/w refractory ascites)
Key point	HRS in Wilson's disease can be compounded by direct copper nephrotoxicity
Management	Terlipressin + albumin; definitive treatment is liver transplantation

Aspect	Detail
Mechanism	Sluggish portal flow in cirrhosis + endothelial damage + hypercoagulable tendency (paradoxically, despite coagulopathy, cirrhotic patients have a "rebalanced" haemostasis with thrombotic risk)
Consequence	Worsens portal hypertension; can precipitate variceal bleeding

Aspect	Detail
Mechanism	Cirrhosis from any cause → chronic hepatocyte injury and regeneration → accumulation of somatic mutations → dysplastic nodules → HCC
Risk in Wilson's	Any cause of cirrhosis is a risk factor for HCC, including Wilson's disease ^[13]. However, the risk of HCC in Wilson's disease is lower than in viral hepatitis-related cirrhosis. The reason is debated — copper may have some anti-proliferative effects, and effective chelation therapy reduces liver damage
Surveillance	All Wilson's disease patients with cirrhosis should undergo 6-monthly USS ± AFP for HCC screening

Aspect	Detail
Mechanism	Liver failure → impaired hepatic clearance of ammonia and other neurotoxins → these reach the brain via portosystemic shunting → astrocyte swelling (Alzheimer type II astrocytosis) → cerebral oedema and functional impairment
Precipitants	GI bleeding (gut bacteria convert blood proteins to ammonia), constipation (prolonged ammonia absorption), infection/sepsis, electrolyte disturbances (hypokalaemia, hyponatraemia), dehydration, sedatives, dietary protein excess (now largely disproven as a major factor) ^[5]
Grading	West Haven criteria: Grade I (sleep disturbance, shortened attention) → Grade IV (coma)
Management	Lactulose (osmotic laxative — ↓ gut transit time → ↓ ammonia absorption; also acidifies colonic lumen → converts NH₃ to NH₄⁺ which cannot cross membranes), rifaximin (non-absorbable antibiotic — reduces ammonia-producing gut bacteria), treat precipitants

Wilson's – Double Encephalopathy

Wilson's disease patients can develop encephalopathy from TWO separate mechanisms: (1) hepatic encephalopathy from liver failure (ammonia-mediated), and (2) copper encephalopathy from direct copper toxicity to the brain (basal ganglia, cerebellum). These are mechanistically distinct and may coexist. Hepatic encephalopathy is typically fluctuating and reversible; copper-related neurological damage may be progressive and less reversible.

Aspect	Detail
Mechanism	Liver failure → ↓ synthesis of clotting factors (II, VII, IX, X — all made in the liver) + ↓ thrombopoietin → thrombocytopenia is compounded by hypersplenism from portal hypertension + impaired clearance of fibrinolytic factors
Clinical consequence	Easy bruising, prolonged bleeding from minor wounds, risk of catastrophic haemorrhage from varices or procedures

Aspect	Detail
Mechanism	Reticuloendothelial dysfunction and reduced opsonisation ^[5] — the liver's Kupffer cells (resident macrophages) are functionally impaired → cannot clear bacteria from the portal circulation. Impaired hepatic synthetic function → reduced complement and opsonin production. Gut bacterial translocation is enhanced
Common organisms	Bacteria — especially from the respiratory and urinary tract; Staph, Strep, gram-negative rods; bacteraemia in up to 25% of fulminant hepatic failure patients. Fungal infection — especially Candida ^[5]
Clinical importance	Sepsis is a major cause of death in liver failure; have a low threshold for blood cultures and empirical antibiotics

These arise from progressive copper deposition in the brain and can occur as the presenting feature or as a complication of ongoing disease.

Complication	Mechanism	Detail
Irreversible neurological damage	Prolonged copper deposition → neuronal death, demyelination, gliosis	If treatment is delayed or the patient is non-compliant, neurological deficits (dystonia, dysarthria, ataxia) may become permanent. Early treatment is critical
Pseudobulbar palsy	Bilateral UMN lesions from copper deposition in brainstem	Dysphagia → risk of aspiration pneumonia (a common cause of morbidity and mortality in neurological Wilson's disease)
Seizures	Cortical copper deposition → neuronal hyperexcitability	Occur in a minority of patients; require anticonvulsant management
Psychiatric decompensation	Copper in cortex and limbic system	Depression, psychosis, personality change — can lead to social dysfunction, non-compliance with treatment, and suicide risk
Treatment-related neurological worsening	Penicillamine causes worsened neurological symptoms in the first few days — patient is used to copper in brain, but once penicillamine is given, they lose copper, body is not used, may exacerbate the neuro symptoms ^[7]	Can be irreversible; this is why trientine is preferred for neurological disease

Complication	Mechanism
Coombs-negative haemolytic anaemia	Associated with acute liver failure but can occur episodically independent of liver failure. Results from effects of excess copper ions on the RBC membrane due to hepatic copper release following cellular necrosis ^[4]
Severe anaemia	Combination of haemolysis + nutritional deficiency (folate consumption from chronic haemolysis) + possible bone marrow suppression from copper toxicity
Thrombocytopenia	Hypersplenism from portal hypertension; also possible direct copper marrow toxicity
Gallstones (pigment stones)	Chronic haemolysis → increased unconjugated bilirubin → pigment gallstone formation → biliary colic, cholecystitis, choledocholithiasis

Complication	Mechanism
Fanconi syndrome	Copper deposition in proximal tubule → generalised proximal tubular transport defect → aminoaciduria, glycosuria, phosphaturia, uricosuria, bicarbonaturia (type 2 RTA)
Nephrolithiasis	Hypercalciuria and hyperuricosuria from tubular dysfunction promote stone formation
Renal tubular acidosis (Type 2)	Bicarbonate wasting → normal anion gap metabolic acidosis
Osteoporosis / Rickets / Osteomalacia	Phosphate wasting (phosphaturia from Fanconi syndrome) → hypophosphataemia → impaired bone mineralisation. Also vitamin D activation may be impaired
Hepatorenal syndrome	See above — in the setting of decompensated cirrhosis

Complication	Detail
Kayser-Fleischer rings	While considered a diagnostic sign, they also represent tissue damage. They fade with effective treatment, which can be used to monitor response
Sunflower cataracts	Copper deposition in the lens — usually does not significantly impair vision, but can contribute to visual symptoms in some patients

Complication	Mechanism
Premature osteoarthritis	Copper deposition in articular cartilage → chondrocyte damage and degradation
Chondrocalcinosis / CPPD disease	Wilson's is a recognised metabolic cause of CPPD crystal deposition; can cause pseudogout attacks
Osteoporosis and pathological fractures	Multi-factorial: Fanconi syndrome (phosphate wasting), chronic liver disease (impaired vitamin D activation, reduced sex hormones), possible direct copper effect on osteoblasts

Complication	Mechanism
Cardiomyopathy	Copper deposition in the myocardium → dilated or hypertrophic cardiomyopathy (rare but described)
Arrhythmias	Copper-induced electrical instability; can also arise from electrolyte disturbances secondary to Fanconi syndrome
Sudden cardiac death	Very rare; from severe cardiomyopathy or arrhythmia

These are iatrogenic complications that arise from the medications used to treat Wilson's disease.

Complication	Drug	Mechanism
Initial neurological worsening	Penicillamine	Rapid mobilisation of hepatic copper → transient spike in free copper → paradoxical worsening ^[7]. Can be irreversible. Prevented by starting at low dose and titrating slowly, or by using trientine instead
Nephrotoxicity (membranous nephropathy)	Penicillamine	Immune complex deposition in glomerular basement membrane → proteinuria → nephrotic syndrome
Drug-induced myasthenia gravis	Penicillamine	Induction of anti-acetylcholine receptor antibodies
Drug-induced lupus	Penicillamine	Induction of ANA and anti-histone antibodies → lupus-like syndrome
Bone marrow suppression	Penicillamine	Aplastic anaemia, agranulocytosis — potentially fatal
Iron/zinc deficiency	Trientine	Chelates iron and zinc → if taken concurrently, forms ineffective complexes
GI upset	Zinc	Nausea, dyspepsia — the most common adverse effect of zinc therapy
Non-compliance	All	Arguably the most dangerous complication of all — adolescent patients are at highest risk. Discontinuation of therapy can lead to rapid reaccumulation of copper, fulminant liver failure, and death

Scenario	Outcome
Never treated	Universally fatal; majority die from liver failure ^[1]
Treatment discontinued	Rapid copper reaccumulation → can present as fulminant liver failure, acute haemolysis, or rapid neurological deterioration — often irreversible
Late diagnosis	Advanced cirrhosis or irreversible neurological damage already present → limited benefit from chelation alone → may require liver transplantation

System	Complications	Key Mechanism
Liver	Acute liver failure, cirrhosis, portal hypertension (varices, ascites, SBP, HRS, hepatic hydrothorax, PVT), HCC, HE, coagulopathy	Direct copper toxicity → hepatocyte damage → fibrosis → cirrhosis → portal hypertension
Neurological	Irreversible movement disorder, pseudobulbar palsy, aspiration pneumonia, seizures, psychiatric decompensation	Copper deposition in basal ganglia, cerebellum, cortex
Haematological	Coombs-negative haemolytic anaemia, thrombocytopenia, pigment gallstones	Copper toxicity to RBCs; hypersplenism; haemolysis by-products
Renal	Fanconi syndrome, RTA, nephrolithiasis, osteoporosis, HRS	Copper deposition in proximal tubules; decompensated cirrhosis
Ophthalmological	KF rings, sunflower cataracts	Copper deposition in Descemet's membrane and lens
MSK	Premature OA, chondrocalcinosis, osteoporosis, fractures	Copper in cartilage; Fanconi phosphaturia
Cardiac	Cardiomyopathy, arrhythmias	Copper deposition in myocardium
Treatment-related	Neurological worsening, nephrotoxicity, MG, lupus, marrow suppression, GI upset	Drug-specific mechanisms (penicillamine, trientine, zinc)

High Yield Summary – Complications

Hepatic complications dominate — ~30% die from hepatic complications if untreated ^[1]; cirrhosis is present in 35–45% at diagnosis
Complications of cirrhosis follow the standard framework: variceal bleeding, ascites, SBP, HRS, hepatic hydrothorax, PVT, HE, HCC, coagulopathy, infections ^[20]
Fulminant liver failure (8–12%) has the specific triad: Coombs-negative haemolysis + low ALP + AST:ALT > 2
Coombs-negative haemolytic anaemia can occur with ALF or episodically independent of liver failure ^[4]
Neurological complications can be irreversible if treatment is delayed — early diagnosis is critical
Penicillamine-induced neurological worsening is a major treatment complication ^[7] — reason to prefer trientine in neurological disease
Fanconi syndrome causes a cascade of renal, metabolic and skeletal complications (RTA, nephrolithiasis, osteoporosis)
HCC risk exists in Wilson's cirrhosis — surveillance with 6-monthly USS ± AFP is required ^[13]
Non-compliance is the most dangerous modifiable complication — discontinuation of lifelong treatment can be fatal
Liver transplantation is curative and is indicated for fulminant liver failure and refractory decompensated cirrhosis ^[19]

Active Recall - Wilson's Disease Complications

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease, Prognosis and Management) ^[4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease – Biochemical tests, Coombs-negative haemolytic anaemia) ^[5] Senior notes: Block A - A jaundiced and incoherent patient_ liver failure.pdf (Complications of liver failure, Infections) ^[7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf (Wilson's – penicillamine neurological worsening, fulminant features) ^[13] Senior notes: Maksim Surgery Notes.pdf (Hepatocellular carcinoma – risk factors including Wilson's disease) ^[19] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Treatment slide) ^[20] Lecture slides: GC 026. Abdominal distension_ascites and cirrhosis.pdf (The Cirrhotic Patient: One-Slide Overview)

High Yield Summary

Wilson's disease = AR mutation in ATP7B gene on chromosome 13 → defective copper-transporting P-type ATPase
Two key functional losses: failure to incorporate copper into ceruloplasmin + failure to excrete copper into bile
Copper accumulates in liver first (from birth) → hepatocyte damage → copper spills into blood → deposits in brain, cornea, kidneys, RBCs
Children present with hepatic disease; older patients with neurological/psychiatric disease
KF rings (Descemet's membrane) present in 99% with neuropsychiatric and 30–50% with hepatic disease
Coombs-negative haemolytic anaemia is the hallmark haematological manifestation — non-immune, direct copper toxicity to RBCs
Fulminant liver failure + Coombs-negative haemolytic anaemia + low ALP in a young patient = think Wilson's
Most patients are compound heterozygotes; > 200 mutations identified
Universally fatal if untreated
Genetic test does not have to be positive to diagnose — clinical + biochemical diagnosis is sufficient given the genetic heterogeneity
Wilson's disease is a recognised metabolic cause of CPPD crystal deposition disease
Can mimic Parkinson's disease — always check copper studies in young-onset parkinsonism

High Yield Summary – Differential Diagnosis

Hepatic DDx: Viral hepatitis (especially HBV in HK), AIH, NAFLD, DILI, haemochromatosis, A1AT deficiency — all can cause chronic liver disease in young patients. Wilson's is distinguished by low ceruloplasmin, elevated urine copper, KF rings.
Neurological DDx: IPD, drug-induced parkinsonism, Huntington's, NBIA — Wilson's presents younger and has systemic features (liver disease, KF rings). Always check copper studies in young-onset movement disorders.
Haematological DDx: All causes of Coombs-negative haemolytic anaemia — Wilson's is distinguished by coexisting liver disease and copper metabolic derangement.
ALF DDx: Viral, paracetamol, AIH — Wilson's ALF has the classic triad: Coombs-negative haemolysis + low ALP + AST:ALT > 2.
Psychiatric DDx: Always investigate organic causes in young patients with new psychiatric symptoms — Wilson's is treatable.
No single test is diagnostic — use the Leipzig scoring system incorporating multiple parameters.
Family screening of first-degree relatives must be undertaken once a proband is identified.

High Yield Summary – Diagnosis

No single test is diagnostic — use the Leipzig scoring system (≥ 4 = diagnosed)
Three core screening tests: ceruloplasmin (< 20 mg/dL), 24h urine copper (> 100 μg), slit-lamp for KF rings
Liver biopsy is the GOLD standard — hepatic Cu ≥ 250 μg/g dry weight is diagnostic, < 50 excludes
Histology mimics AIH and NASH — always request quantitative copper alongside histology
ATP7B genetic testing is NOT used for initial diagnosis due to genetic heterogeneity; reserved for unclear cases and family screening
AST > ALT (ratio > 2) is a characteristic LFT pattern; low ALP is a clue in fulminant Wilson's
Fulminant Wilson's ALF clues: Coombs-negative haemolysis + ALP:bilirubin < 4 + AST:ALT > 2.2
Family screening of first-degree relatives must be undertaken — begin with mutation analysis if proband's mutations are known
MRI brain: T2 hyperintensity in basal ganglia; "face of giant panda sign" in midbrain
KF rings present in 99% with neuropsychiatric disease but only 30–50% with hepatic disease

High Yield Summary – Management

Treatment is lifelong — discontinuation leads to relapse and death
Symptomatic patients → copper chelator (penicillamine or trientine) for initial de-coppering
Penicillamine: lower cost, preferred first-line; co-prescribe vitamin B6; S/E include initial neurological worsening, nephrotoxicity, MG, drug-induced lupus ^[3]^[7]
Trientine: preferred for neurological disease because penicillamine causes initial worsening; chelates iron/zinc → separate by 1 hour ^[3]
Oral Zinc: maintenance treatment in asymptomatic patients ^[3]; mechanism = induces metallothionein in enterocytes
Liver transplantation = effective cure; indicated for fulminant hepatic failure (coagulopathy + encephalopathy + Coombs-negative haemolysis + rapid deterioration within 8 weeks) and refractory decompensated cirrhosis ^[19]
Liver transplantation NOT indicated if only for neurologic disease ^[19]
Haemodialysis for rapid copper removal in acute liver failure ^[3]
Genetic counselling and family screening of first-degree relatives are mandatory ^[3]^[8]
Prognosis: excellent if treated (86% 5-year survival); universally fatal if untreated ^[1]

High Yield Summary – Complications

Hepatic complications dominate — ~30% die from hepatic complications if untreated ^[1]; cirrhosis is present in 35–45% at diagnosis
Complications of cirrhosis follow the standard framework: variceal bleeding, ascites, SBP, HRS, hepatic hydrothorax, PVT, HE, HCC, coagulopathy, infections ^[20]
Fulminant liver failure (8–12%) has the specific triad: Coombs-negative haemolysis + low ALP + AST:ALT > 2
Coombs-negative haemolytic anaemia can occur with ALF or episodically independent of liver failure ^[4]
Neurological complications can be irreversible if treatment is delayed — early diagnosis is critical
Penicillamine-induced neurological worsening is a major treatment complication ^[7] — reason to prefer trientine in neurological disease
Fanconi syndrome causes a cascade of renal, metabolic and skeletal complications (RTA, nephrolithiasis, osteoporosis)
HCC risk exists in Wilson's cirrhosis — surveillance with 6-monthly USS ± AFP is required ^[13]
Non-compliance is the most dangerous modifiable complication — discontinuation of lifelong treatment can be fatal
Liver transplantation is curative and is indicated for fulminant liver failure and refractory decompensated cirrhosis ^[19]

Wilson's Disease

Definition

Epidemiology

Risk Factors

Anatomy and Normal Copper Physiology

Normal Copper Metabolism — First Principles

Relevant Anatomy — Copper Deposition Sites

Aetiology and Pathophysiology

Genetic Basis

Pathophysiology — Step by Step

Pathophysiology of Specific Organ Damage

Liver Damage

Brain Damage

Corneal Damage (Kayser-Fleischer Rings)

Renal Damage

Haematological Damage

Classification

By Predominant Organ Involvement

By Hepatic Presentation

Leipzig Scoring System (Diagnostic — preview)

Clinical Features

Natural History

Symptoms

A. Hepatic Symptoms

B. Neurological Symptoms

C. Psychiatric Symptoms

D. Other Symptoms

Signs

A. Hepatic Signs

B. Ophthalmic Signs

C. Neurological Signs

D. Renal Signs

E. Haematological Signs

F. Musculoskeletal Signs

G. Other Signs

Summary of Clinical Features by System

Active Recall - Wilson's Disease (Part 1: Definition to Clinical Features)

References

Why Differential Diagnosis Matters in Wilson's Disease

Approach to the Differential Diagnosis — By Presenting Phenotype

1. Hepatic Presentation — DDx of Unexplained Liver Disease in a Young Patient

2. Neurological Presentation — DDx of Young-Onset Movement Disorder

3. Psychiatric Presentation — DDx of Young-Onset Psychiatric Symptoms

4. Haematological Presentation — DDx of Coombs-Negative Haemolytic Anaemia

5. Acute Liver Failure — DDx in a Young Patient

6. Miscellaneous DDx by System

Renal (Fanconi Syndrome)

Musculoskeletal (Chondrocalcinosis / CPPD)

Ophthalmological (KF Rings)

Summary Table — Key Differentiators for Wilson's Disease vs Major Mimics

Diagnostic Approach to "Is This Wilson's Disease?" — Decision Framework

Active Recall - Wilson's Disease Differential Diagnosis

Guiding Principle — Why Is Diagnosis Difficult?

When to Suspect Wilson's Disease

Investigation Modalities — Detailed Breakdown

A. First-Line Screening Investigations

1. Serum Ceruloplasmin

2. 24-Hour Urinary Copper Excretion

3. Slit-Lamp Examination for Kayser-Fleischer (KF) Rings

4. Serum Copper

B. Second-Line / Confirmatory Investigations

5. Liver Biopsy with Quantitative Hepatic Copper Concentration

6. Mutation Analysis (ATP7B Genotyping)

C. Supportive / Ancillary Investigations

7. Complete Blood Count (CBC) with Reticulocyte Count and Blood Film

8. Direct Coombs Test (Direct Antiglobulin Test, DAT)

9. Liver Function Tests (LFT)

10. Clotting Profile

11. HBV and HCV Serology

12. Other Bloods

D. Radiological Investigations

13. Ultrasound Abdomen

14. MRI Brain

15. Other Imaging

Diagnostic Criteria

A. Felix Lai / EASL-Style Combination Criteria

B. Leipzig Scoring System (Ferenci Score)

C. Criteria for Fulminant Wilson's Disease (Wilson's ALF)

Diagnostic Algorithm — Mermaid Diagram

Family Screening Protocol